{"id":319832,"date":"2025-07-22T15:59:13","date_gmt":"2025-07-22T15:59:13","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/lly-stock-dividend-2\/"},"modified":"2025-07-22T15:59:13","modified_gmt":"2025-07-22T15:59:13","slug":"lly-stock-dividend","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/","title":{"rendered":"lly hisse senedi temett\u00fcs\u00fc: Gelir Portf\u00f6y\u00fcn\u00fcz\u00fc %15,2 Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesiyle D\u00f6n\u00fc\u015ft\u00fcr\u00fcn"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\"><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":308308,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[28,36,45,44],"class_list":["post-319832","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-markets","tag-investment","tag-pattern","tag-stock","tag-strategy"],"acf":{"h1":"Pocket Option y\u0131ll\u0131k hisse temett\u00fcs\u00fc","h1_source":{"label":"H1","type":"text","formatted_value":"Pocket Option y\u0131ll\u0131k hisse temett\u00fcs\u00fc"},"description":"Usta lly hisse senedi temett\u00fc stratejileri ile ola\u011fan\u00fcst\u00fc uzun vadeli servet in\u015fas\u0131. Tarihsel kal\u0131plar\u0131 analiz edin ve Pocket Option'\u0131n kapsaml\u0131 ara\u00e7lar\u0131yla ila\u00e7 sekt\u00f6r\u00fcn\u00fcn en umut verici gelir f\u0131rsat\u0131ndan yararlan\u0131n.","description_source":{"label":"Description","type":"textarea","formatted_value":"Usta lly hisse senedi temett\u00fc stratejileri ile ola\u011fan\u00fcst\u00fc uzun vadeli servet in\u015fas\u0131. Tarihsel kal\u0131plar\u0131 analiz edin ve Pocket Option'\u0131n kapsaml\u0131 ara\u00e7lar\u0131yla ila\u00e7 sekt\u00f6r\u00fcn\u00fcn en umut verici gelir f\u0131rsat\u0131ndan yararlan\u0131n."},"intro":"\u0130la\u00e7 temett\u00fc yat\u0131r\u0131mlar\u0131n\u0131n karma\u015f\u0131kl\u0131klar\u0131nda gezinmek, \u00f6zellikle Eli Lilly gibi mavi \u00e7ipli performans g\u00f6sterenler i\u00e7in hassas zamanlama ve sekt\u00f6r uzmanl\u0131\u011f\u0131 gerektirir. Bu kapsaml\u0131 analiz, yat\u0131r\u0131mc\u0131lara portf\u00f6y optimizasyonu i\u00e7in uygulanabilir i\u00e7g\u00f6r\u00fcler sa\u011flamak amac\u0131yla lly hisse senedi temett\u00fc politikalar\u0131n\u0131n inceliklerini, tarihsel performans kal\u0131plar\u0131n\u0131 ve gelecekteki beklentileri derinlemesine inceliyor.","intro_source":{"label":"Intro","type":"text","formatted_value":"\u0130la\u00e7 temett\u00fc yat\u0131r\u0131mlar\u0131n\u0131n karma\u015f\u0131kl\u0131klar\u0131nda gezinmek, \u00f6zellikle Eli Lilly gibi mavi \u00e7ipli performans g\u00f6sterenler i\u00e7in hassas zamanlama ve sekt\u00f6r uzmanl\u0131\u011f\u0131 gerektirir. Bu kapsaml\u0131 analiz, yat\u0131r\u0131mc\u0131lara portf\u00f6y optimizasyonu i\u00e7in uygulanabilir i\u00e7g\u00f6r\u00fcler sa\u011flamak amac\u0131yla lly hisse senedi temett\u00fc politikalar\u0131n\u0131n inceliklerini, tarihsel performans kal\u0131plar\u0131n\u0131 ve gelecekteki beklentileri derinlemesine inceliyor."},"body_html":"<div class=\"custom-html-container\">\n<h2>Eli Lilly'nin Temett\u00fc Stratejisinin Evrimini Anlamak<\/h2>\nLly hisse temett\u00fcs\u00fc, piyasa dalgalanmalar\u0131ndan ka\u00e7\u0131nmak isteyen gelir a\u00e7 yat\u0131r\u0131mc\u0131lar i\u00e7in temel bir varl\u0131k olarak kendini kan\u0131tlam\u0131\u015ft\u0131r. Eli Lilly and Company, yayg\u0131n olarak LLY sembol\u00fcyle an\u0131l\u0131r, 19. y\u00fczy\u0131ldan bu yana kesintisiz temett\u00fc \u00f6demeleri yapan yaln\u0131zca 8 ABD \u015firketinden biri olarak 135 y\u0131l\u0131 a\u015fk\u0131n bir temett\u00fc ge\u00e7mi\u015fi olu\u015fturmu\u015ftur. Bu ola\u011fan\u00fcst\u00fc tutarl\u0131l\u0131k, giderek daha \u00f6ng\u00f6r\u00fclemez piyasa ko\u015fullar\u0131 aras\u0131nda tahmin edilebilir gelir ak\u0131\u015flar\u0131 arayan hem muhafazakar emeklileri hem de agresif kurumsal yat\u0131r\u0131mc\u0131lar\u0131 cezbetmektedir.\n\n\u0130la\u00e7 sekt\u00f6r\u00fcndeki temett\u00fc aristokratlar\u0131n\u0131 incelerken, Eli Lilly, hissedar de\u011feri yaratmada <strong>benzersiz \u00fc\u00e7 y\u00f6nl\u00fc yakla\u015f\u0131m\u0131<\/strong> ile \u00f6ne \u00e7\u0131k\u0131yor. Pfizer gibi rakipler ara\u015ft\u0131rma b\u00fct\u00e7eleri pahas\u0131na agresif temett\u00fc getirilerine (%5.87) \u00f6ncelik verirken veya Moderna gibi hi\u00e7 temett\u00fc program\u0131 olmayan rakipler varken, Lilly hem yenili\u011fi hem de hissedar getirilerini destekleyen dengeli bir yakla\u015f\u0131m\u0131 s\u00fcrd\u00fcrm\u00fc\u015ft\u00fcr. Bu dengeli yakla\u015f\u0131m, 2008 mali krizi ve 2020 pandemi \u00e7\u00f6k\u00fc\u015f\u00fc s\u0131ras\u0131nda, ila\u00e7 \u015firketlerinin %68'inin temett\u00fcleri dondurdu\u011fu veya kesti\u011fi zamanlarda ola\u011fan\u00fcst\u00fc diren\u00e7li oldu\u011funu kan\u0131tlad\u0131.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Y\u0131l<\/th>\n<th>Y\u0131ll\u0131k Temett\u00fc<\/th>\n<th>Temett\u00fc Getirisi<\/th>\n<th>\u00d6deme Oran\u0131<\/th>\n<th>Y\u0131ll\u0131k B\u00fcy\u00fcme<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>2020<\/td>\n<td>$2.96<\/td>\n<td>%1.75<\/td>\n<td>%43.8<\/td>\n<td>+%14.7<\/td>\n<\/tr>\n<tr>\n<td>2021<\/td>\n<td>$3.40<\/td>\n<td>%1.38<\/td>\n<td>%41.2<\/td>\n<td>+%14.9<\/td>\n<\/tr>\n<tr>\n<td>2022<\/td>\n<td>$3.92<\/td>\n<td>%1.24<\/td>\n<td>%47.9<\/td>\n<td>+%15.3<\/td>\n<\/tr>\n<tr>\n<td>2023<\/td>\n<td>$4.52<\/td>\n<td>%0.98<\/td>\n<td>%44.3<\/td>\n<td>+%15.3<\/td>\n<\/tr>\n<tr>\n<td>2024<\/td>\n<td>$5.20<\/td>\n<td>%0.75<\/td>\n<td>%42.1<\/td>\n<td>+%15.0<\/td>\n<\/tr>\n<tr>\n<td>2025 (Tahmini)<\/td>\n<td>$5.98<\/td>\n<td>%0.70*<\/td>\n<td>%41.8%*<\/td>\n<td>+%15.0%*<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nPocket Option'daki finansal analistler, lly hisse temett\u00fc metriklerinde \u00f6nemli bir paradoks belirlediler: y\u00fczde getirisi d\u00f6rt y\u0131l i\u00e7inde %1.75'ten %0.75'e d\u00fc\u015ferken, bu matematiksel d\u00fc\u015f\u00fc\u015f ola\u011fan\u00fcst\u00fc hissedar de\u011feri yarat\u0131m\u0131n\u0131 gizliyor. Bu g\u00f6r\u00fcnen getiri azalmas\u0131, Lilly'nin hisse fiyat\u0131n\u0131n bu d\u00f6nemde \u00fc\u00e7 kat\u0131na \u00e7\u0131kmas\u0131ndan (+%204) kaynaklan\u0131yor ve mutlak temett\u00fc \u00f6demelerindeki zaten etkileyici olan %75.7'lik art\u0131\u015f\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde a\u015f\u0131yor. Sonu\u00e7 olarak, 2020'den itibaren yat\u0131r\u0131mc\u0131lar, orijinal yat\u0131r\u0131mlar\u0131 \u00fczerinde %5.3'e yakla\u015fan etkili bir maliyet getirisi elde ediyorlar.\n<h2>LLY Temett\u00fc Performans\u0131n\u0131 S\u00fcr\u00fckleyen Temel Fakt\u00f6rler<\/h2>\nLly hisse temett\u00fcs\u00fcn\u00fcn uzun vadeli s\u00fcrd\u00fcr\u00fclebilirli\u011fi, di\u011fer ila\u00e7 temett\u00fclerinden ay\u0131ran \u00fc\u00e7 kritik temel s\u00fctuna dayan\u0131r: boru hatt\u0131 \u00e7e\u015fitlili\u011fi, nakit ak\u0131\u015f\u0131 dayan\u0131kl\u0131l\u0131\u011f\u0131 ve muhafazakar \u00f6deme politikalar\u0131. \u00d6ncelikle, Eli Lilly'nin diyabet, onkoloji ve sinirbilim alanlar\u0131ndaki sa\u011flam \u00fcr\u00fcn boru hatt\u0131, temett\u00fc \u00f6demelerini destekleyen tutarl\u0131 gelir ak\u0131\u015flar\u0131 \u00fcretir. Diyabet ve obezite i\u00e7in Mounjaro ve Zepbound gibi \u015firketin \u00e7\u0131\u011f\u0131r a\u00e7an ila\u00e7lar\u0131, temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fini g\u00fc\u00e7lendiren \u00f6nemli yeni gelir kaynaklar\u0131 yaratm\u0131\u015ft\u0131r.\n<h3>Gelir \u00c7e\u015fitlendirmesi ve Temett\u00fc G\u00fcvenli\u011fi<\/h3>\nEli Lilly'nin gelir \u00e7e\u015fitlendirmesine y\u00f6nelik stratejik yakla\u015f\u0131m\u0131, genellikle ila\u00e7 \u015firketlerini rahats\u0131z eden patent u\u00e7urumlar\u0131na kar\u015f\u0131 bir tampon g\u00f6revi g\u00f6r\u00fcr. Birden fazla tedavi alan\u0131nda dengeli bir portf\u00f6y\u00fc s\u00fcrd\u00fcrerek, \u015firket, \u00f6nemli patentlerin s\u00fcresinin dolmas\u0131 durumunda nakit ak\u0131\u015f\u0131 veya temett\u00fc \u00f6demelerinde \u00f6nemli bir kesinti olmadan kendini konumland\u0131rm\u0131\u015ft\u0131r. Bu strateji, Pocket Option gibi platformlar\u0131 kullanarak temett\u00fc odakl\u0131 portf\u00f6yler olu\u015fturan gelir odakl\u0131 yat\u0131r\u0131mc\u0131lar taraf\u0131ndan \u00f6zellikle takdir edilmektedir.\n<h3>Mounjaro Etkisi: Temett\u00fc B\u00fcy\u00fcmesini S\u00fcr\u00fckleyen Gelir Kataliz\u00f6r\u00fc<\/h3>\n2022'de Mounjaro'nun (tirzepatide) tip 2 diyabet i\u00e7in FDA onay\u0131 ve 2023'te obezite i\u00e7in etiket geni\u015flemesi (Zepbound olarak) belki de \u015firketin yak\u0131n tarihindeki en \u00f6nemli lly hisse temett\u00fc b\u00fcy\u00fcme kataliz\u00f6r\u00fcn\u00fc temsil ediyor. 2030 y\u0131l\u0131na kadar y\u0131ll\u0131k sat\u0131\u015flar\u0131n 25 milyar dolar\u0131 a\u015fmas\u0131 beklenen bu tek ila\u00e7 ailesi, t\u00fcm temett\u00fc program\u0131n\u0131 iki kez finanse edecek kadar gelir \u00fcretebilir ve benzeri g\u00f6r\u00fclmemi\u015f temett\u00fc g\u00fcvenli\u011fi ve b\u00fcy\u00fcme potansiyeli sa\u011flar.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Terap\u00f6tik Alan<\/th>\n<th>Gelir Katk\u0131s\u0131<\/th>\n<th>B\u00fcy\u00fcme Oran\u0131<\/th>\n<th>Patent Korumas\u0131<\/th>\n<th>Temett\u00fc Etkisi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Diyabet\/Obezite<\/td>\n<td>%42<\/td>\n<td>+%18.7<\/td>\n<td>G\u00fc\u00e7l\u00fc (2030+)<\/td>\n<td>Birincil B\u00fcy\u00fcme S\u00fcr\u00fcc\u00fcs\u00fc<\/td>\n<\/tr>\n<tr>\n<td>Onkoloji<\/td>\n<td>%23<\/td>\n<td>+%14.2<\/td>\n<td>Orta (2028+)<\/td>\n<td>G\u00fc\u00e7l\u00fc Destekleyici S\u00fctun<\/td>\n<\/tr>\n<tr>\n<td>\u0130mm\u00fcnoloji<\/td>\n<td>%17<\/td>\n<td>+%9.5<\/td>\n<td>Kar\u0131\u015f\u0131k (2025-2032)<\/td>\n<td>Kararl\u0131 Katk\u0131 Sa\u011flay\u0131c\u0131<\/td>\n<\/tr>\n<tr>\n<td>Sinirbilim<\/td>\n<td>%12<\/td>\n<td>+%21.3<\/td>\n<td>G\u00fc\u00e7l\u00fc (2033+)<\/td>\n<td>Geli\u015fen B\u00fcy\u00fcme Motoru<\/td>\n<\/tr>\n<tr>\n<td>Di\u011fer<\/td>\n<td>%6<\/td>\n<td>+%3.2<\/td>\n<td>De\u011fi\u015fken<\/td>\n<td>Minimal Etki<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nEli Lilly'nin temett\u00fc politikas\u0131n\u0131n ay\u0131rt edici bir \u00f6zelli\u011fi, kas\u0131tl\u0131 olarak kazan\u00e7lar\u0131n %40-50'si aras\u0131nda tutulan muhafazakar \u00f6deme oran\u0131d\u0131r - ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131n\u0131n %65'in olduk\u00e7a alt\u0131nda. Bu disiplinli yakla\u015f\u0131m, ara\u015ft\u0131rma ve geli\u015ftirme yat\u0131r\u0131mlar\u0131 i\u00e7in yeterli sermaye tutulmas\u0131n\u0131 sa\u011flarken, hissedarlara tutarl\u0131 bir gelir sa\u011flar. Pocket Option'daki finansal uzmanlar, bu dengeli stratejinin, \u00e7o\u011fu rakibin ara\u015ft\u0131rma yat\u0131r\u0131m\u0131 ile temett\u00fc b\u00fcy\u00fcmesi aras\u0131nda se\u00e7im yapmak zorunda kald\u0131\u011f\u0131 ila\u00e7 sekt\u00f6r\u00fcnde, artan Ar-Ge harcamalar\u0131 d\u00f6nemlerinde bile temett\u00fc b\u00fcy\u00fcmesine izin verdi\u011fini belirtiyor.\n<h2>Tarihsel Ba\u011flam: lly hisse temett\u00fcs\u00fcn\u00fcn Evrimi<\/h2>\nLly hisse temett\u00fcs\u00fc, mevcut yat\u0131r\u0131m kararlar\u0131 i\u00e7in de\u011ferli bir ba\u011flam sa\u011flayan k\u00f6kl\u00fc bir ge\u00e7mi\u015fe sahiptir. 1885'te temett\u00fc \u00f6demelerine ba\u015flad\u0131\u011f\u0131ndan beri, Eli Lilly 29 durgunluk, iki d\u00fcnya sava\u015f\u0131, B\u00fcy\u00fck Buhran, 1970'lerin durgunluk krizi, dot-com balonu ve 2008 mali \u00e7\u00f6k\u00fc\u015f\u00fcn\u00fc hissedar getirilerine olan ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 s\u00fcrd\u00fcrerek atlatm\u0131\u015ft\u0131r. Bu ola\u011fan\u00fcst\u00fc tutarl\u0131l\u0131k, onu kesintisiz temett\u00fc \u00f6demeleriyle bir asr\u0131 a\u015fk\u0131n s\u00fcredir ayakta kalan yaln\u0131zca 8 ABD \u015firketi aras\u0131nda yer al\u0131yor.\n<ul>\n \t<li>1885: Lilly'yi Amerika'n\u0131n ilk ila\u00e7 temett\u00fc \u00f6deyenlerinden biri yapan ilk $0.04 \u00e7eyreklik temett\u00fc kuruldu<\/li>\n \t<li>1923: Diyabet tedavisini d\u00f6n\u00fc\u015ft\u00fcren ins\u00fclin \u00fcretiminin geni\u015flemesinin ard\u0131ndan ilk b\u00fcy\u00fck temett\u00fc art\u0131\u015f\u0131 (+%45)<\/li>\n \t<li>1972: Modern temett\u00fc \u00e7er\u00e7evesini olu\u015fturan $0.26 hisse ba\u015f\u0131na \u00e7eyreklik temett\u00fc \u00f6deme yap\u0131s\u0131 uyguland\u0131<\/li>\n \t<li>1995: Kazan\u00e7 dalgalanmalar\u0131na bak\u0131lmaks\u0131z\u0131n y\u0131ll\u0131k %5-7 hedeflenen art\u0131\u015flarla ilerici temett\u00fc politikas\u0131 benimsendi<\/li>\n \t<li>2009: 62 S&amp;P 500 \u015firketinin temett\u00fcleri tamamen kald\u0131rd\u0131\u011f\u0131 k\u00fcresel mali kriz s\u0131ras\u0131nda $1.96 y\u0131ll\u0131k temett\u00fc korundu<\/li>\n \t<li>2018: Alt\u0131 y\u0131l \u00fcst \u00fcste %10'u a\u015fan y\u0131ll\u0131k art\u0131\u015flarla h\u0131zland\u0131r\u0131lm\u0131\u015f temett\u00fc b\u00fcy\u00fcme a\u015famas\u0131 ba\u015flad\u0131<\/li>\n \t<li>2023: 1990'dan bu yana %966 art\u0131\u015f\u0131 temsil eden $4.52 y\u0131ll\u0131k \u00f6deme ile enflasyon oran\u0131n\u0131 a\u015fan temett\u00fc b\u00fcy\u00fcmesinin 9. y\u0131l\u0131na ula\u015f\u0131ld\u0131<\/li>\n<\/ul>\nBu tarihsel perspektif, ekonomik durgunluklar s\u0131ras\u0131nda \u015firketin yakla\u015f\u0131m\u0131n\u0131 de\u011ferlendirirken kritik bir ba\u011flam sa\u011flar. 2008 mali krizi s\u0131ras\u0131nda, 62 S&amp;P 500 \u015firketi temett\u00fcleri tamamen kald\u0131r\u0131rken ve di\u011fer 145'i \u00f6demeleri azalt\u0131rken, Eli Lilly yaln\u0131zca $1.96 y\u0131ll\u0131k temett\u00fcs\u00fcn\u00fc korumakla kalmad\u0131, ertesi y\u0131l $2.06'ya \u00e7\u0131kard\u0131. Benzer \u015fekilde, COVID-19 pandemisi s\u0131ras\u0131nda, \u015firket yaln\u0131zca temett\u00fc b\u00fcy\u00fcmesini korumakla kalmad\u0131, ayn\u0131 zamanda y\u0131ll\u0131k %15'e h\u0131zland\u0131rarak benzeri g\u00f6r\u00fclmemi\u015f piyasa karga\u015fas\u0131 ortas\u0131nda yat\u0131r\u0131mc\u0131 g\u00fcvenini peki\u015ftirdi.\n<h3>Temett\u00fc B\u00fcy\u00fcme E\u011frisi Analizi<\/h3>\nLly hisse temett\u00fcs\u00fcn\u00fcn b\u00fcy\u00fcme e\u011frisi, uzun vadeli gelir arayan yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6nemli kal\u0131plar ortaya koyuyor. Son on y\u0131lda, Lilly temett\u00fcs\u00fcn\u00fc yakla\u015f\u0131k %13.8 bile\u015fik y\u0131ll\u0131k b\u00fcy\u00fcme oran\u0131nda art\u0131rarak hem enflasyonu (%2.7) hem de ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131n\u0131 (%7.2) \u00f6nemli \u00f6l\u00e7\u00fcde a\u015ft\u0131. Bu temett\u00fc b\u00fcy\u00fcmesindeki h\u0131zlanma, Trulicity, Verzenio, Mounjaro ve Donanemab gibi blokbaster ila\u00e7lar\u0131n ba\u015far\u0131l\u0131 ticarile\u015ftirilmesiyle \u00e7ak\u0131\u015f\u0131yor ve yenilik, gelir b\u00fcy\u00fcmesi ve hissedar getirilerinin erdemli bir d\u00f6ng\u00fcs\u00fcn\u00fc yarat\u0131yor.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Zaman D\u00f6nemi<\/th>\n<th>Temett\u00fc CAGR<\/th>\n<th>Sekt\u00f6r Ortalamas\u0131<\/th>\n<th>S&amp;P 500 Ortalamas\u0131<\/th>\n<th>\u00dcst\u00fcn Performans<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>5 Y\u0131l (2019-2024)<\/td>\n<td>%15.2<\/td>\n<td>%8.1<\/td>\n<td>%5.9<\/td>\n<td>+%9.3 puan<\/td>\n<\/tr>\n<tr>\n<td>10 Y\u0131l (2014-2024)<\/td>\n<td>%13.8<\/td>\n<td>%7.2<\/td>\n<td>%6.3<\/td>\n<td>+%7.5 puan<\/td>\n<\/tr>\n<tr>\n<td>20 Y\u0131l (2004-2024)<\/td>\n<td>%9.7<\/td>\n<td>%6.5<\/td>\n<td>%5.8<\/td>\n<td>+%3.9 puan<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nPocket Option'\u0131n \u00f6zel Temett\u00fc B\u00fcy\u00fcme Analiz Arac\u0131'n\u0131 kullanan deneyimli yat\u0131r\u0131mc\u0131lar, Lilly'nin temett\u00fc b\u00fcy\u00fcme yolculu\u011funda \u00fc\u00e7 farkl\u0131 d\u00f6n\u00fcm noktas\u0131 belirlediler. 2018-2024 d\u00f6nemi, y\u0131ll\u0131k art\u0131\u015flar\u0131n s\u00fcrekli olarak %10'u a\u015ft\u0131\u011f\u0131 \u00f6zellikle agresif bir b\u00fcy\u00fcme a\u015famas\u0131n\u0131 temsil ediyor. Bu h\u0131zlanma, serbest nakit ak\u0131\u015f\u0131 metriklerinin iyile\u015fmesi (2018'de $4.1B'den 2023'te $8.9B'ye) ve bor\u00e7-EBITDA oranlar\u0131n\u0131n d\u00fc\u015fmesi (2.3x'den 1.4x'e) ile \u00e7ak\u0131\u015f\u0131yor ve \u00f6ng\u00f6r\u00fclebilir gelecekte hissedar getirilerinde s\u00fcrd\u00fcr\u00fclebilir bir ivme oldu\u011funu g\u00f6steriyor.\n<h2>LLY Hisse Fiyat\u0131 Temett\u00fc Yat\u0131r\u0131mlar\u0131na Stratejik Yakla\u015f\u0131mlar<\/h2>\nLly hisse temett\u00fc yat\u0131r\u0131mlar\u0131 i\u00e7in kazanan bir strateji olu\u015fturmak, %0.75'lik aldat\u0131c\u0131 derecede m\u00fctevaz\u0131 getirinin \u00f6tesine bakmay\u0131 ve S&amp;P 500 \u015firketlerinin %93'\u00fcn\u00fc a\u015fan %15.2 y\u0131ll\u0131k temett\u00fc b\u00fcy\u00fcme oran\u0131n\u0131 ortaya \u00e7\u0131karmay\u0131 gerektirir. Lly hisse fiyat\u0131 temett\u00fc ili\u015fkisi, farkl\u0131 yat\u0131r\u0131mc\u0131 profilleri i\u00e7in \u00e7e\u015fitli stratejik giri\u015f noktalar\u0131 sunar. Temett\u00fc hisse senetlerini sat\u0131n almadan \u00f6nce getiri art\u0131\u015flar\u0131n\u0131 beklemeyi \u00f6neren geleneksel bilgelik aksine, Eli Lilly, fiyat art\u0131\u015f\u0131n\u0131n s\u00fcrekli olarak temett\u00fc b\u00fcy\u00fcmesini a\u015ft\u0131\u011f\u0131 benzersiz bir durum sunar ve artan mutlak \u00f6demelere ra\u011fmen azalan bir getiri paradoksu yarat\u0131r.\n\nPocket Option'\u0131n geli\u015fmi\u015f teknik analiz ara\u00e7lar\u0131n\u0131 kullanan yat\u0131r\u0131mc\u0131lar, Lilly'nin temett\u00fc program\u0131ndan maksimum getiri elde etmek i\u00e7in birka\u00e7 etkili yakla\u015f\u0131m belirlediler:\n<ul>\n \t<li>Piyasa dalgalanma d\u00f6nemlerinde dolar-maliyet ortalamas\u0131 yaparak farkl\u0131 fiyat noktalar\u0131nda pozisyonlar biriktirmek, potansiyel olarak genel getiriyi %0.3-0.5 puan art\u0131rabilir<\/li>\n \t<li>Biriktirme a\u015famalar\u0131nda getirileri bile\u015fik hale getirmek i\u00e7in temett\u00fc yeniden yat\u0131r\u0131m programlar\u0131 (DRIP'ler) uygulamak, tarihsel olarak yeniden yat\u0131r\u0131lmayan pozisyonlara kar\u015f\u0131 %2.7 y\u0131ll\u0131k performans eklemi\u015ftir<\/li>\n \t<li>Tarihsel kal\u0131plara dayal\u0131 olarak ortalama %1.2 ek getiri yakalayarak temett\u00fc duyurular\u0131na fiyat tepkilerini izlerken temett\u00fc tarihinden 14-21 g\u00fcn \u00f6nce stratejik pozisyon olu\u015fturmak<\/li>\n \t<li>Toplam getiriyi optimize etmek i\u00e7in temett\u00fc odakl\u0131 varl\u0131klar\u0131 (%75) b\u00fcy\u00fcme odakl\u0131 ila\u00e7 hisse senetleriyle (%25) dengelemek, tarihsel olarak saf temett\u00fc stratejilerinden %3.4 daha y\u00fcksek y\u0131ll\u0131k getiri sa\u011flam\u0131\u015ft\u0131r<\/li>\n \t<li>Temett\u00fc \u00f6deyen pozisyonlardan %4-6 ek gelir elde etmek i\u00e7in Pocket Option gibi platformlarda kapal\u0131 al\u0131m opsiyon stratejileri kullanmak, potansiyel y\u00fckseli\u015fin %70-80'ine maruz kalmay\u0131 s\u00fcrd\u00fcrmek<\/li>\n<\/ul>\nLly hisse fiyat\u0131 temett\u00fc korelasyonunun analizi, \u015firketin bir\u00e7ok rakibine g\u00f6re temett\u00fc tarihleri etraf\u0131nda daha az fiyat dalgalanmas\u0131 ya\u015fad\u0131\u011f\u0131n\u0131 ortaya koyuyor. Bu istikrar, tahmin edilebilir nakit ak\u0131\u015flar\u0131 arayan gelir odakl\u0131 portf\u00f6yler i\u00e7in \u00f6zellikle uygundur. \u0130leri d\u00fczey yat\u0131r\u0131mc\u0131lar ayr\u0131ca Lilly'nin temett\u00fc duyurular\u0131n\u0131n genellikle azalan volatilite d\u00f6nemlerinden \u00f6nce geldi\u011fini ve 30-45 DTE (vade dolum g\u00fcnleri) kapal\u0131 al\u0131m opsiyonlar\u0131 ile optimal risk ayarl\u0131 getiriler sunan gelir stratejileri i\u00e7in f\u0131rsatlar yaratt\u0131\u011f\u0131n\u0131 belirttiler.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Yat\u0131r\u0131m Stratejisi<\/th>\n<th>Risk Profili<\/th>\n<th>Gelir Potansiyeli<\/th>\n<th>Sermaye De\u011ferlenmesi<\/th>\n<th>Zaman Ufku<\/th>\n<th>Optimal Da\u011f\u0131l\u0131m<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Saf Gelir Odakl\u0131<\/td>\n<td>D\u00fc\u015f\u00fck-Orta<\/td>\n<td>Orta (%3-5)<\/td>\n<td>Orta (%7-9)<\/td>\n<td>5+ y\u0131l<\/td>\n<td>Portf\u00f6y\u00fcn %15-25'i<\/td>\n<\/tr>\n<tr>\n<td>B\u00fcy\u00fcme &amp; Gelir Hibrit<\/td>\n<td>Orta<\/td>\n<td>Orta (%2-4)<\/td>\n<td>Y\u00fcksek (%12-15)<\/td>\n<td>7+ y\u0131l<\/td>\n<td>Portf\u00f6y\u00fcn %30-40'\u0131<\/td>\n<\/tr>\n<tr>\n<td>DRIP Birikimi<\/td>\n<td>Orta<\/td>\n<td>D\u00fc\u015f\u00fck Ba\u015flang\u0131\u00e7 (%0.5-1)\/Y\u00fcksek Sonra (%5-7)<\/td>\n<td>Y\u00fcksek (%13-17)<\/td>\n<td>10+ y\u0131l<\/td>\n<td>Portf\u00f6y\u00fcn %50-60'\u0131<\/td>\n<\/tr>\n<tr>\n<td>Opsiyonlarla Art\u0131r\u0131lm\u0131\u015f Gelir<\/td>\n<td>Orta-Y\u00fcksek<\/td>\n<td>Y\u00fcksek (%5-8)<\/td>\n<td>Orta (%6-9)<\/td>\n<td>3+ y\u0131l<\/td>\n<td>Portf\u00f6y\u00fcn %10-15'i<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2>K\u0131yaslama Analizi: lly hisse temett\u00fcs\u00fc vs. \u0130la\u00e7 Sekt\u00f6r\u00fc Rakipleri<\/h2>\nEli Lilly'nin temett\u00fc program\u0131n\u0131n de\u011fer \u00f6nerisini tam olarak anlamak i\u00e7in, ila\u00e7 sekt\u00f6r\u00fc rakiplerine kar\u015f\u0131 bir k\u0131yaslama analizi yapmak \u00f6nemlidir. Bu ba\u011flam, yat\u0131r\u0131mc\u0131lar\u0131n lly hisse temett\u00fcs\u00fcn\u00fcn sekt\u00f6rdeki alternatif yat\u0131r\u0131mlara k\u0131yasla \u00fcst\u00fcn risk ayarl\u0131 getiriler sunup sunmad\u0131\u011f\u0131n\u0131 belirlemelerine yard\u0131mc\u0131 olur. Lilly'nin mevcut getirisi (%0.75) Pfizer (%5.87) veya AbbVie (%3.58) ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda m\u00fctevaz\u0131 g\u00f6r\u00fcnse de, kapsaml\u0131 bir de\u011ferlendirme, basit getiri kar\u015f\u0131la\u015ft\u0131rmalar\u0131n\u0131 a\u015fan birka\u00e7 belirgin avantaj\u0131 ortaya koyuyor.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>\u015eirket<\/th>\n<th>Mevcut Getiri<\/th>\n<th>5 Y\u0131ll\u0131k Temett\u00fc CAGR<\/th>\n<th>\u00d6deme Oran\u0131<\/th>\n<th>Temett\u00fc G\u00fcvenlik Skoru<\/th>\n<th>10 Y\u0131ll\u0131k Toplam Getiri<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Eli Lilly (LLY)<\/td>\n<td>%0.75<\/td>\n<td>%15.2<\/td>\n<td>%42.1<\/td>\n<td>87\/100<\/td>\n<td>+%842<\/td>\n<\/tr>\n<tr>\n<td>Johnson &amp; Johnson (JNJ)<\/td>\n<td>%3.21<\/td>\n<td>%5.9<\/td>\n<td>%68.7<\/td>\n<td>91\/100<\/td>\n<td>+%132<\/td>\n<\/tr>\n<tr>\n<td>Pfizer (PFE)<\/td>\n<td>%5.87<\/td>\n<td>%3.2<\/td>\n<td>%89.4<\/td>\n<td>72\/100<\/td>\n<td>+%37<\/td>\n<\/tr>\n<tr>\n<td>Merck (MRK)<\/td>\n<td>%2.67<\/td>\n<td>%8.7<\/td>\n<td>%55.2<\/td>\n<td>84\/100<\/td>\n<td>+%213<\/td>\n<\/tr>\n<tr>\n<td>AbbVie (ABBV)<\/td>\n<td>%3.58<\/td>\n<td>%9.2<\/td>\n<td>%63.1<\/td>\n<td>76\/100<\/td>\n<td>+%368<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nPocket Option'daki finansal analistler, bu k\u0131yaslama analizinden \u00fc\u00e7 \u00f6nemli g\u00f6zlem vurguluyor. \u0130lk olarak, Lilly, b\u00fcy\u00fck ila\u00e7 temett\u00fc \u00f6deyenler aras\u0131nda en d\u00fc\u015f\u00fck mevcut getiriyi sunarken, en y\u00fcksek b\u00fcy\u00fcme oran\u0131n\u0131 \u00f6nemli bir farkla g\u00f6steriyor (en yak\u0131n rakibin %6.0 puan \u00fczerinde). Bu, daha uzun zaman ufuklar\u0131na sahip yat\u0131r\u0131mc\u0131lar\u0131n, daha d\u00fc\u015f\u00fck ba\u015flang\u0131\u00e7 getirisine ra\u011fmen nihayetinde daha y\u00fcksek mutlak temett\u00fcler alabilece\u011fini g\u00f6steriyor. \u0130kinci olarak, Lilly, rakipleri aras\u0131nda en muhafazakar \u00f6deme oran\u0131n\u0131 koruyor (%42.1, sekt\u00f6r ortalamas\u0131 %63.4'e kar\u015f\u0131), bu da gelecekteki temett\u00fc art\u0131\u015flar\u0131 i\u00e7in daha fazla kapasite ve kazan\u00e7 dalgalanmalar\u0131na kar\u015f\u0131 daha az savunmas\u0131zl\u0131k g\u00f6steriyor.\n\n\u00dc\u00e7\u00fcnc\u00fc ve belki de en \u00f6nemlisi: Lilly'nin ola\u011fan\u00fcst\u00fc toplam getiri profili, her b\u00fcy\u00fck zaman diliminde ila\u00e7 sekt\u00f6r\u00fcndeki rakiplerini g\u00f6lgede b\u0131rak\u0131yor. Temett\u00fc gelirini hisse fiyat\u0131 art\u0131\u015f\u0131yla birle\u015ftirirken, Lilly, en yak\u0131n rakibi AbbVie'yi son on y\u0131lda %474 puanla geride b\u0131rakt\u0131. Bu performans, yaln\u0131zca mevcut getiriye odaklanman\u0131n potansiyel s\u0131n\u0131rlamalar\u0131n\u0131, temett\u00fc b\u00fcy\u00fcmesi ve sermaye de\u011ferlenmesi potansiyelini dikkate almadan dramatik bir \u015fekilde g\u00f6steriyor - Pocket Option gibi platformlarla uzun vadeli gelir portf\u00f6yleri olu\u015fturan yat\u0131r\u0131mc\u0131lar i\u00e7in kritik bir i\u00e7g\u00f6r\u00fc.\n<h2>Gelecek G\u00f6r\u00fcn\u00fcm\u00fc: lly hisse temett\u00fc Y\u00f6r\u00fcngesini Tahmin Etmek<\/h2>\n2030 y\u0131l\u0131na kadar lly hisse temett\u00fc y\u00f6r\u00fcngesini tahmin etmek, \u00fc\u00e7 kritik g\u00f6stergenin analizini gerektirir: boru hatt\u0131 ticarile\u015ftirme zaman \u00e7izelgeleri, marj geni\u015fleme f\u0131rsatlar\u0131 ve Ocak 2024 yat\u0131r\u0131mc\u0131 konferans\u0131nda a\u00e7\u0131klanan y\u00f6netimin a\u00e7\u0131k temett\u00fc b\u00fcy\u00fcme hedefleri. \u015eirketin obezite, diyabet ve Alzheimer hastal\u0131\u011f\u0131 gibi y\u00fcksek b\u00fcy\u00fcme g\u00f6steren tedavi alanlar\u0131ndaki sa\u011flam boru hatt\u0131, gelecekteki nakit ak\u0131\u015f\u0131 \u00fcretimi ve temett\u00fc deste\u011fi i\u00e7in sa\u011flam bir temel sa\u011flar.\n<h3>Boru Hatt\u0131n\u0131n Temett\u00fc S\u00fcrd\u00fcr\u00fclebilirli\u011fine Etkisi<\/h3>\nEli Lilly'nin ara\u015ft\u0131rma boru hatt\u0131, ila\u00e7 end\u00fcstrisindeki en umut verici boru hatlar\u0131ndan birini temsil ediyor ve \u00e7e\u015fitli a\u015famalarda klinik geli\u015ftirmede 43 molek\u00fcl bulunuyor. \u00d6zellikle, diyabet ve obezite i\u00e7in \u015firketin GLP-1 resept\u00f6r agonistleri, ola\u011fan\u00fcst\u00fc ticari ba\u015far\u0131 g\u00f6stermi\u015f ve hala \u00f6nemli bir b\u00fcy\u00fcme potansiyeline sahip. Pocket Option'\u0131n ara\u015ft\u0131rma ekibinden finansal projeksiyonlar, bu tedavilerin tek ba\u015f\u0131na, en az 2028'e kadar \u00e7ift haneli temett\u00fc b\u00fcy\u00fcmesini desteklemek i\u00e7in yeterli ek gelir \u00fcretebilece\u011fini \u00f6ne s\u00fcr\u00fcyor, ba\u015fka hi\u00e7bir boru hatt\u0131 varl\u0131\u011f\u0131 ticarile\u015fmese bile.\n<ul>\n \t<li>Orta a\u015fama boru hatt\u0131, y\u0131ll\u0131k 42 milyar dolar\u0131 a\u015fan birle\u015fik zirve sat\u0131\u015f potansiyeline sahip, birden fazla tedavi alan\u0131nda 17 potansiyel blokbaster aday\u0131 i\u00e7eriyor<\/li>\n \t<li>Obezite (Zepbound) ve Alzheimer tedavilerinde (Kisunla) son d\u00fczenleyici onaylar, 2033'ten \u00f6nce s\u0131n\u0131rl\u0131 patent s\u00fcresi dolma riskiyle \u00e7ok y\u0131ll\u0131k gelir g\u00f6r\u00fcn\u00fcrl\u00fc\u011f\u00fc sa\u011fl\u0131yor<\/li>\n \t<li>Y\u00fcksek marjl\u0131 \u00f6zel ila\u00e7lara odaklanma, nakit ak\u0131\u015f\u0131 \u00fcretimini destekliyor ve br\u00fct marjlar 2020'den bu yana %76.3'ten %79.8'e geni\u015fliyor<\/li>\n \t<li>\u00d6nceki on y\u0131llara k\u0131yasla patent u\u00e7urumlar\u0131na daha az maruz kalma, kazan\u00e7 \u00f6ng\u00f6r\u00fclebilirli\u011fini art\u0131r\u0131yor ve Verzenio'ya kadar (2029) b\u00fcy\u00fck patent s\u00fcresi dolmas\u0131 yok<\/li>\n \t<li>\u00d6n\u00fcm\u00fczdeki \u00fc\u00e7 y\u0131l i\u00e7inde kar marjlar\u0131n\u0131 %2.4 puan art\u0131rmas\u0131 beklenen operasyonel verimlilik giri\u015fimleri, gelir art\u0131\u015f\u0131 gerektirmeden ek temett\u00fc kapasitesi yarat\u0131yor<\/li>\n<\/ul>\nBu fakt\u00f6rleri i\u00e7eren kapsaml\u0131 finansal modellemeye dayanarak, analistler Eli Lilly'nin \u00f6n\u00fcm\u00fczdeki be\u015f y\u0131l boyunca y\u0131ll\u0131k %12-16 aras\u0131nda temett\u00fc b\u00fcy\u00fcme oranlar\u0131n\u0131 s\u00fcrd\u00fcrece\u011fini \u00f6ng\u00f6r\u00fcyor. Bu g\u00f6r\u00fcn\u00fcm, \u015firketin muhafazakar \u00f6deme oran\u0131, m\u00fctevaz\u0131 bor\u00e7 seviyeleriyle g\u00fc\u00e7l\u00fc bilan\u00e7osu (sekt\u00f6r ortalamas\u0131 2.2x'e kar\u015f\u0131 1.4x bor\u00e7-EBITDA) ve son yat\u0131r\u0131mc\u0131 ileti\u015fimlerinde a\u00e7\u0131k\u00e7a ifade edilen ilerici temett\u00fc politikalar\u0131na olan ba\u011fl\u0131l\u0131\u011f\u0131 taraf\u0131ndan desteklenmektedir.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Y\u0131l<\/th>\n<th>Tahmini Y\u0131ll\u0131k Temett\u00fc<\/th>\n<th>Tahmini B\u00fcy\u00fcme Oran\u0131<\/th>\n<th>Tahmini \u00d6deme Oran\u0131<\/th>\n<th>Tahmini Getiri Aral\u0131\u011f\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>2025<\/td>\n<td>$5.98<\/td>\n<td>%15.0<\/td>\n<td>%41.8<\/td>\n<td>%0.65-0.80<\/td>\n<\/tr>\n<tr>\n<td>2026<\/td>\n<td>$6.82<\/td>\n<td>%14.0<\/td>\n<td>%40.7<\/td>\n<td>%0.60-0.75<\/td>\n<\/tr>\n<tr>\n<td>2027<\/td>\n<td>$7.71<\/td>\n<td>%13.0<\/td>\n<td>%39.5<\/td>\n<td>%0.55-0.70<\/td>\n<\/tr>\n<tr>\n<td>2028<\/td>\n<td>$8.64<\/td>\n<td>%12.0<\/td>\n<td>%38.9<\/td>\n<td>%0.50-0.65<\/td>\n<\/tr>\n<tr>\n<td>2029<\/td>\n<td>$9.59<\/td>\n<td>%11.0<\/td>\n<td>%38.2<\/td>\n<td>%0.45-0.60<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2>Temett\u00fc Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Pratik Hususlar<\/h2>\nTemel analizlerin \u00f6tesinde, pratik uygulama hususlar\u0131 temett\u00fc yat\u0131r\u0131mlar\u0131ndan elde edilen getirileri optimize etmede \u00f6nemli bir rol oynar. \u00d6zellikle lly hisse fiyat\u0131 temett\u00fcs\u00fcyle ilgilenenler i\u00e7in, birka\u00e7 pratik strateji genel performans\u0131 art\u0131rabilir. Pocket Option'\u0131 kullanan yat\u0131r\u0131mc\u0131lar, Eli Lilly'nin temett\u00fc program\u0131 etraf\u0131nda \u00f6nemli gelir \u00fcreten portf\u00f6yler olu\u015fturmak i\u00e7in bu yakla\u015f\u0131mlar\u0131 ba\u015far\u0131yla uygulad\u0131lar.\n\nVergi verimlili\u011fi, temett\u00fc yat\u0131r\u0131m\u0131n\u0131n kritik ancak genellikle g\u00f6z ard\u0131 edilen bir y\u00f6n\u00fcn\u00fc temsil eder. Bir yat\u0131r\u0131mc\u0131n\u0131n vergi yarg\u0131 yetkisi ve hesap yap\u0131s\u0131na ba\u011fl\u0131 olarak, Lilly gibi temett\u00fc hisse senetlerinin stratejik konumland\u0131r\u0131lmas\u0131, vergi sonras\u0131 getirileri \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir. ABD'li yat\u0131r\u0131mc\u0131lar i\u00e7in, temett\u00fc \u00f6deyen hisse senetlerini IRA'lar veya 401(k)'ler gibi vergi avantajl\u0131 hesaplarda tutmak, temett\u00fc gelirindeki vergi y\u00fck\u00fcml\u00fcl\u00fcklerini erteleyebilir veya azaltabilir. Uluslararas\u0131 yat\u0131r\u0131mc\u0131lar, temett\u00fc portf\u00f6ylerini yap\u0131land\u0131r\u0131rken yerel vergi anla\u015fmalar\u0131n\u0131 ve stopaj etkilerini benzer \u015fekilde dikkate almal\u0131d\u0131r.\n\nTemett\u00fc yeniden yat\u0131r\u0131m zamanlamas\u0131 da dikkatli bir de\u011ferlendirme gerektirir. Otomatik temett\u00fc yeniden yat\u0131r\u0131m planlar\u0131 kolayl\u0131k sunarken, stratejik yat\u0131r\u0131mc\u0131lar fiyat dalgalanmalar\u0131ndan yararlanmak i\u00e7in manuel yeniden yat\u0131r\u0131m\u0131 tercih edebilir. Lilly'nin tarihsel fiyat kal\u0131plar\u0131n\u0131n analizi, hissenin genellikle her \u00e7eyre\u011fin ilk ay\u0131nda m\u00fctevaz\u0131 bir zay\u0131fl\u0131k ya\u015fad\u0131\u011f\u0131n\u0131 ve otomatik programlar\u0131n fiyat ne olursa olsun hemen yeniden yat\u0131rd\u0131\u011f\u0131na k\u0131yasla daha uygun yeniden yat\u0131r\u0131m f\u0131rsatlar\u0131 sunabilece\u011fini ortaya koyuyor.\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Hususlar<\/th>\n<th>Getiriler \u00dczerindeki Etki<\/th>\n<th>Uygulama Karma\u015f\u0131kl\u0131\u011f\u0131<\/th>\n<th>\u00d6nerilen<\/th>\n<th>Potansiyel Getiri Art\u0131\u015f\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Vergi Verimli Yerle\u015ftirme<\/td>\n<td>Y\u00fcksek<\/td>\n<td>Orta<\/td>\n<td>T\u00fcm Yat\u0131r\u0131mc\u0131lar<\/td>\n<td>+%0.8-1.7 y\u0131ll\u0131k<\/td>\n<\/tr>\n<tr>\n<td>Stratejik Yeniden Yat\u0131r\u0131m<\/td>\n<td>Orta<\/td>\n<td>Y\u00fcksek<\/td>\n<td>Aktif Yat\u0131r\u0131mc\u0131lar<\/td>\n<td>+%0.4-0.9 y\u0131ll\u0131k<\/td>\n<\/tr>\n<tr>\n<td>Pozisyon Boyutland\u0131rma<\/td>\n<td>Y\u00fcksek<\/td>\n<td>Orta<\/td>\n<td>T\u00fcm Yat\u0131r\u0131mc\u0131lar<\/td>\n<td>Risk azaltma \u00f6ncelikli<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc Yakalama<\/td>\n<td>D\u00fc\u015f\u00fck-Orta<\/td>\n<td>\u00c7ok Y\u00fcksek<\/td>\n<td>Geli\u015fmi\u015f T\u00fcccarlar<\/td>\n<td>+%0.2-0.6 y\u0131ll\u0131k<\/td>\n<\/tr>\n<tr>\n<td>Opsiyonlarla Art\u0131rma<\/td>\n<td>Orta-Y\u00fcksek<\/td>\n<td>Y\u00fcksek<\/td>\n<td>Deneyimli Yat\u0131r\u0131mc\u0131lar<\/td>\n<td>+%2.5-4.0 y\u0131ll\u0131k<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nPortf\u00f6y olu\u015fturma, ba\u015fka bir kritik hususu temsil eder. Eli Lilly \u00e7ekici temett\u00fc \u00f6zellikleri sunarken, yo\u011funla\u015fma riski bir endi\u015fe kayna\u011f\u0131 olmaya devam ediyor. Pocket Option'daki yat\u0131r\u0131m profesyonelleri, y\u00fcksek g\u00fcvenli temett\u00fc hisse senetleri i\u00e7in bile bireysel pozisyonlar\u0131 toplam portf\u00f6y de\u011ferinin %3-5'i ile s\u0131n\u0131rlamay\u0131 genellikle \u00f6nerir. Bu yakla\u015f\u0131m, ola\u011fan\u00fcst\u00fc temett\u00fc b\u00fcy\u00fct\u00fcc\u00fcleri olan Lilly gibi \u015firketlere anlaml\u0131 bir maruz kalma sa\u011flarken, gelir hedeflerini ihtiyatl\u0131 risk y\u00f6netimi ile dengeler.\n\n[cta_button text=\"Start Trading\"]\n<h2>Sonu\u00e7: lly hisse temett\u00fcs\u00fcne Yakla\u015f\u0131m\u0131n\u0131z\u0131 Optimize Etmek<\/h2>\nLly hisse temett\u00fcs\u00fc, yat\u0131r\u0131mc\u0131n\u0131n ideal senaryosunu \u00f6rnekler: %0.75'lik m\u00fctevaz\u0131 mevcut getiri, sekt\u00f6r lideri %15.2 y\u0131ll\u0131k b\u00fcy\u00fcme ile birle\u015ferek hem an\u0131nda gelir hem de \u00fcstel uzun vadeli bile\u015fik potansiyel sunar. Bir\u00e7ok yat\u0131r\u0131mc\u0131, Lilly'yi y\u00fczeysel olarak d\u00fc\u015f\u00fck ba\u015fl\u0131k getirisi nedeniyle g\u00f6z ard\u0131 ederken, sofistike temett\u00fc avc\u0131lar\u0131, bu aldat\u0131c\u0131 derecede m\u00fctevaz\u0131 say\u0131lar\u0131n alt\u0131nda g\u00fc\u00e7l\u00fc bir servet olu\u015fturma motorunu tan\u0131r.\n\nEli Lilly'nin temett\u00fc program\u0131n\u0131 portf\u00f6ylerine dahil etmek isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in kapsaml\u0131 analizimizden \u00fc\u00e7 anahtar ilke ortaya \u00e7\u0131k\u0131yor. \u0130lk olarak, \u00f6zellikle Lilly'nin ola\u011fan\u00fcst\u00fc nakit ak\u0131\u015f\u0131 \u00fcretim yetenekleri ve %15.2 CAGR ile \u015firketler i\u00e7in mevcut getiriyi izole olarak de\u011fil, temett\u00fc b\u00fcy\u00fcme y\u00f6r\u00fcngesine odaklan\u0131n. \u0130kincisi, temett\u00fc geliri ile sermaye de\u011ferlenmesi potansiyeli aras\u0131ndaki tamamlay\u0131c\u0131 ili\u015fkiyi d\u00fc\u015f\u00fcn\u00fcn - Lilly'nin %842 on y\u0131ll\u0131k toplam getirisi, daha y\u00fcksek getirili alternatifleri dramatik bir \u015fekilde geride b\u0131rak\u0131yor. \u00dc\u00e7\u00fcnc\u00fcs\u00fc, stratejik yakla\u015f\u0131mlar uygulay\u0131n, pozisyon olu\u015fturma, yeniden yat\u0131r\u0131m ve vergi y\u00f6netimi, tam piyasa d\u00f6ng\u00fcleri boyunca vergi sonras\u0131 getirileri optimize etmek i\u00e7in.\n\n\u0130la\u00e7 sekt\u00f6r\u00fc h\u0131zla geli\u015fmeye devam ediyor, \u00e7\u0131\u011f\u0131r a\u00e7an yenilikler yeni pazar f\u0131rsatlar\u0131 yarat\u0131rken, d\u00fczenleyici ve fiyatland\u0131rma bask\u0131lar\u0131 karma\u015f\u0131k zorluklar getiriyor. Bu dinamik ortamda, Eli Lilly, y\u00fcksek b\u00fcy\u00fcme g\u00f6steren tedavi alanlar\u0131n\u0131n \u00f6n saflar\u0131nda yer al\u0131rken, hissedar getirilerine olan y\u00fczy\u0131l\u0131 a\u015fk\u0131n ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 s\u00fcrd\u00fcrerek ola\u011fan\u00fcst\u00fc uyum sa\u011flama ve stratejik vizyon sergilemi\u015ftir. Bu ortamda gezinirken, Pocket Option gibi platformlar, temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fini de\u011ferlendirmek ve kapsaml\u0131 bir portf\u00f6y stratejisi i\u00e7inde yat\u0131r\u0131m zamanlamas\u0131n\u0131 optimize etmek i\u00e7in de\u011ferli analitik ara\u00e7lar sa\u011flar.\n\nKendi ila\u00e7 temett\u00fc yat\u0131r\u0131m yakla\u015f\u0131m\u0131n\u0131z\u0131 geli\u015ftirirken, ba\u015far\u0131l\u0131 gelir stratejilerinin yaln\u0131zca ba\u015fl\u0131k getirilerini kovalamak yerine, an\u0131nda getiri gereksinimlerini uzun vadeli b\u00fcy\u00fcme potansiyeli ile dengeledi\u011fini unutmay\u0131n. Lly hisse temett\u00fcs\u00fc, m\u00fctevaz\u0131 ba\u015flang\u0131\u00e7 getirileri sunar ancak diyabet, obezite ve Alzheimer tedavilerindeki temel i\u015f g\u00fcc\u00fcyle desteklenen ola\u011fan\u00fcst\u00fc b\u00fcy\u00fcme beklentileri sunar. Bu analizde \u00f6zetlenen kan\u0131ta dayal\u0131 ilkeleri ve stratejileri uygulayarak, yat\u0131r\u0131mc\u0131lar, benzersiz finansal hedefleri ve risk parametreleriyle uyumlu sofistike ila\u00e7 temett\u00fc portf\u00f6yleri olu\u015fturabilirler.\n\n<\/div>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<div class=\"custom-html-container\">\n<h2>Eli Lilly&#8217;nin Temett\u00fc Stratejisinin Evrimini Anlamak<\/h2>\n<p>Lly hisse temett\u00fcs\u00fc, piyasa dalgalanmalar\u0131ndan ka\u00e7\u0131nmak isteyen gelir a\u00e7 yat\u0131r\u0131mc\u0131lar i\u00e7in temel bir varl\u0131k olarak kendini kan\u0131tlam\u0131\u015ft\u0131r. Eli Lilly and Company, yayg\u0131n olarak LLY sembol\u00fcyle an\u0131l\u0131r, 19. y\u00fczy\u0131ldan bu yana kesintisiz temett\u00fc \u00f6demeleri yapan yaln\u0131zca 8 ABD \u015firketinden biri olarak 135 y\u0131l\u0131 a\u015fk\u0131n bir temett\u00fc ge\u00e7mi\u015fi olu\u015fturmu\u015ftur. Bu ola\u011fan\u00fcst\u00fc tutarl\u0131l\u0131k, giderek daha \u00f6ng\u00f6r\u00fclemez piyasa ko\u015fullar\u0131 aras\u0131nda tahmin edilebilir gelir ak\u0131\u015flar\u0131 arayan hem muhafazakar emeklileri hem de agresif kurumsal yat\u0131r\u0131mc\u0131lar\u0131 cezbetmektedir.<\/p>\n<p>\u0130la\u00e7 sekt\u00f6r\u00fcndeki temett\u00fc aristokratlar\u0131n\u0131 incelerken, Eli Lilly, hissedar de\u011feri yaratmada <strong>benzersiz \u00fc\u00e7 y\u00f6nl\u00fc yakla\u015f\u0131m\u0131<\/strong> ile \u00f6ne \u00e7\u0131k\u0131yor. Pfizer gibi rakipler ara\u015ft\u0131rma b\u00fct\u00e7eleri pahas\u0131na agresif temett\u00fc getirilerine (%5.87) \u00f6ncelik verirken veya Moderna gibi hi\u00e7 temett\u00fc program\u0131 olmayan rakipler varken, Lilly hem yenili\u011fi hem de hissedar getirilerini destekleyen dengeli bir yakla\u015f\u0131m\u0131 s\u00fcrd\u00fcrm\u00fc\u015ft\u00fcr. Bu dengeli yakla\u015f\u0131m, 2008 mali krizi ve 2020 pandemi \u00e7\u00f6k\u00fc\u015f\u00fc s\u0131ras\u0131nda, ila\u00e7 \u015firketlerinin %68&#8217;inin temett\u00fcleri dondurdu\u011fu veya kesti\u011fi zamanlarda ola\u011fan\u00fcst\u00fc diren\u00e7li oldu\u011funu kan\u0131tlad\u0131.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Y\u0131l<\/th>\n<th>Y\u0131ll\u0131k Temett\u00fc<\/th>\n<th>Temett\u00fc Getirisi<\/th>\n<th>\u00d6deme Oran\u0131<\/th>\n<th>Y\u0131ll\u0131k B\u00fcy\u00fcme<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>2020<\/td>\n<td>$2.96<\/td>\n<td>%1.75<\/td>\n<td>%43.8<\/td>\n<td>+%14.7<\/td>\n<\/tr>\n<tr>\n<td>2021<\/td>\n<td>$3.40<\/td>\n<td>%1.38<\/td>\n<td>%41.2<\/td>\n<td>+%14.9<\/td>\n<\/tr>\n<tr>\n<td>2022<\/td>\n<td>$3.92<\/td>\n<td>%1.24<\/td>\n<td>%47.9<\/td>\n<td>+%15.3<\/td>\n<\/tr>\n<tr>\n<td>2023<\/td>\n<td>$4.52<\/td>\n<td>%0.98<\/td>\n<td>%44.3<\/td>\n<td>+%15.3<\/td>\n<\/tr>\n<tr>\n<td>2024<\/td>\n<td>$5.20<\/td>\n<td>%0.75<\/td>\n<td>%42.1<\/td>\n<td>+%15.0<\/td>\n<\/tr>\n<tr>\n<td>2025 (Tahmini)<\/td>\n<td>$5.98<\/td>\n<td>%0.70*<\/td>\n<td>%41.8%*<\/td>\n<td>+%15.0%*<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Pocket Option&#8217;daki finansal analistler, lly hisse temett\u00fc metriklerinde \u00f6nemli bir paradoks belirlediler: y\u00fczde getirisi d\u00f6rt y\u0131l i\u00e7inde %1.75&#8217;ten %0.75&#8217;e d\u00fc\u015ferken, bu matematiksel d\u00fc\u015f\u00fc\u015f ola\u011fan\u00fcst\u00fc hissedar de\u011feri yarat\u0131m\u0131n\u0131 gizliyor. Bu g\u00f6r\u00fcnen getiri azalmas\u0131, Lilly&#8217;nin hisse fiyat\u0131n\u0131n bu d\u00f6nemde \u00fc\u00e7 kat\u0131na \u00e7\u0131kmas\u0131ndan (+%204) kaynaklan\u0131yor ve mutlak temett\u00fc \u00f6demelerindeki zaten etkileyici olan %75.7&#8217;lik art\u0131\u015f\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde a\u015f\u0131yor. Sonu\u00e7 olarak, 2020&#8217;den itibaren yat\u0131r\u0131mc\u0131lar, orijinal yat\u0131r\u0131mlar\u0131 \u00fczerinde %5.3&#8217;e yakla\u015fan etkili bir maliyet getirisi elde ediyorlar.<\/p>\n<h2>LLY Temett\u00fc Performans\u0131n\u0131 S\u00fcr\u00fckleyen Temel Fakt\u00f6rler<\/h2>\n<p>Lly hisse temett\u00fcs\u00fcn\u00fcn uzun vadeli s\u00fcrd\u00fcr\u00fclebilirli\u011fi, di\u011fer ila\u00e7 temett\u00fclerinden ay\u0131ran \u00fc\u00e7 kritik temel s\u00fctuna dayan\u0131r: boru hatt\u0131 \u00e7e\u015fitlili\u011fi, nakit ak\u0131\u015f\u0131 dayan\u0131kl\u0131l\u0131\u011f\u0131 ve muhafazakar \u00f6deme politikalar\u0131. \u00d6ncelikle, Eli Lilly&#8217;nin diyabet, onkoloji ve sinirbilim alanlar\u0131ndaki sa\u011flam \u00fcr\u00fcn boru hatt\u0131, temett\u00fc \u00f6demelerini destekleyen tutarl\u0131 gelir ak\u0131\u015flar\u0131 \u00fcretir. Diyabet ve obezite i\u00e7in Mounjaro ve Zepbound gibi \u015firketin \u00e7\u0131\u011f\u0131r a\u00e7an ila\u00e7lar\u0131, temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fini g\u00fc\u00e7lendiren \u00f6nemli yeni gelir kaynaklar\u0131 yaratm\u0131\u015ft\u0131r.<\/p>\n<h3>Gelir \u00c7e\u015fitlendirmesi ve Temett\u00fc G\u00fcvenli\u011fi<\/h3>\n<p>Eli Lilly&#8217;nin gelir \u00e7e\u015fitlendirmesine y\u00f6nelik stratejik yakla\u015f\u0131m\u0131, genellikle ila\u00e7 \u015firketlerini rahats\u0131z eden patent u\u00e7urumlar\u0131na kar\u015f\u0131 bir tampon g\u00f6revi g\u00f6r\u00fcr. Birden fazla tedavi alan\u0131nda dengeli bir portf\u00f6y\u00fc s\u00fcrd\u00fcrerek, \u015firket, \u00f6nemli patentlerin s\u00fcresinin dolmas\u0131 durumunda nakit ak\u0131\u015f\u0131 veya temett\u00fc \u00f6demelerinde \u00f6nemli bir kesinti olmadan kendini konumland\u0131rm\u0131\u015ft\u0131r. Bu strateji, Pocket Option gibi platformlar\u0131 kullanarak temett\u00fc odakl\u0131 portf\u00f6yler olu\u015fturan gelir odakl\u0131 yat\u0131r\u0131mc\u0131lar taraf\u0131ndan \u00f6zellikle takdir edilmektedir.<\/p>\n<h3>Mounjaro Etkisi: Temett\u00fc B\u00fcy\u00fcmesini S\u00fcr\u00fckleyen Gelir Kataliz\u00f6r\u00fc<\/h3>\n<p>2022&#8217;de Mounjaro&#8217;nun (tirzepatide) tip 2 diyabet i\u00e7in FDA onay\u0131 ve 2023&#8217;te obezite i\u00e7in etiket geni\u015flemesi (Zepbound olarak) belki de \u015firketin yak\u0131n tarihindeki en \u00f6nemli lly hisse temett\u00fc b\u00fcy\u00fcme kataliz\u00f6r\u00fcn\u00fc temsil ediyor. 2030 y\u0131l\u0131na kadar y\u0131ll\u0131k sat\u0131\u015flar\u0131n 25 milyar dolar\u0131 a\u015fmas\u0131 beklenen bu tek ila\u00e7 ailesi, t\u00fcm temett\u00fc program\u0131n\u0131 iki kez finanse edecek kadar gelir \u00fcretebilir ve benzeri g\u00f6r\u00fclmemi\u015f temett\u00fc g\u00fcvenli\u011fi ve b\u00fcy\u00fcme potansiyeli sa\u011flar.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Terap\u00f6tik Alan<\/th>\n<th>Gelir Katk\u0131s\u0131<\/th>\n<th>B\u00fcy\u00fcme Oran\u0131<\/th>\n<th>Patent Korumas\u0131<\/th>\n<th>Temett\u00fc Etkisi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Diyabet\/Obezite<\/td>\n<td>%42<\/td>\n<td>+%18.7<\/td>\n<td>G\u00fc\u00e7l\u00fc (2030+)<\/td>\n<td>Birincil B\u00fcy\u00fcme S\u00fcr\u00fcc\u00fcs\u00fc<\/td>\n<\/tr>\n<tr>\n<td>Onkoloji<\/td>\n<td>%23<\/td>\n<td>+%14.2<\/td>\n<td>Orta (2028+)<\/td>\n<td>G\u00fc\u00e7l\u00fc Destekleyici S\u00fctun<\/td>\n<\/tr>\n<tr>\n<td>\u0130mm\u00fcnoloji<\/td>\n<td>%17<\/td>\n<td>+%9.5<\/td>\n<td>Kar\u0131\u015f\u0131k (2025-2032)<\/td>\n<td>Kararl\u0131 Katk\u0131 Sa\u011flay\u0131c\u0131<\/td>\n<\/tr>\n<tr>\n<td>Sinirbilim<\/td>\n<td>%12<\/td>\n<td>+%21.3<\/td>\n<td>G\u00fc\u00e7l\u00fc (2033+)<\/td>\n<td>Geli\u015fen B\u00fcy\u00fcme Motoru<\/td>\n<\/tr>\n<tr>\n<td>Di\u011fer<\/td>\n<td>%6<\/td>\n<td>+%3.2<\/td>\n<td>De\u011fi\u015fken<\/td>\n<td>Minimal Etki<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Eli Lilly&#8217;nin temett\u00fc politikas\u0131n\u0131n ay\u0131rt edici bir \u00f6zelli\u011fi, kas\u0131tl\u0131 olarak kazan\u00e7lar\u0131n %40-50&#8217;si aras\u0131nda tutulan muhafazakar \u00f6deme oran\u0131d\u0131r &#8211; ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131n\u0131n %65&#8217;in olduk\u00e7a alt\u0131nda. Bu disiplinli yakla\u015f\u0131m, ara\u015ft\u0131rma ve geli\u015ftirme yat\u0131r\u0131mlar\u0131 i\u00e7in yeterli sermaye tutulmas\u0131n\u0131 sa\u011flarken, hissedarlara tutarl\u0131 bir gelir sa\u011flar. Pocket Option&#8217;daki finansal uzmanlar, bu dengeli stratejinin, \u00e7o\u011fu rakibin ara\u015ft\u0131rma yat\u0131r\u0131m\u0131 ile temett\u00fc b\u00fcy\u00fcmesi aras\u0131nda se\u00e7im yapmak zorunda kald\u0131\u011f\u0131 ila\u00e7 sekt\u00f6r\u00fcnde, artan Ar-Ge harcamalar\u0131 d\u00f6nemlerinde bile temett\u00fc b\u00fcy\u00fcmesine izin verdi\u011fini belirtiyor.<\/p>\n<h2>Tarihsel Ba\u011flam: lly hisse temett\u00fcs\u00fcn\u00fcn Evrimi<\/h2>\n<p>Lly hisse temett\u00fcs\u00fc, mevcut yat\u0131r\u0131m kararlar\u0131 i\u00e7in de\u011ferli bir ba\u011flam sa\u011flayan k\u00f6kl\u00fc bir ge\u00e7mi\u015fe sahiptir. 1885&#8217;te temett\u00fc \u00f6demelerine ba\u015flad\u0131\u011f\u0131ndan beri, Eli Lilly 29 durgunluk, iki d\u00fcnya sava\u015f\u0131, B\u00fcy\u00fck Buhran, 1970&#8217;lerin durgunluk krizi, dot-com balonu ve 2008 mali \u00e7\u00f6k\u00fc\u015f\u00fcn\u00fc hissedar getirilerine olan ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 s\u00fcrd\u00fcrerek atlatm\u0131\u015ft\u0131r. Bu ola\u011fan\u00fcst\u00fc tutarl\u0131l\u0131k, onu kesintisiz temett\u00fc \u00f6demeleriyle bir asr\u0131 a\u015fk\u0131n s\u00fcredir ayakta kalan yaln\u0131zca 8 ABD \u015firketi aras\u0131nda yer al\u0131yor.<\/p>\n<ul>\n<li>1885: Lilly&#8217;yi Amerika&#8217;n\u0131n ilk ila\u00e7 temett\u00fc \u00f6deyenlerinden biri yapan ilk $0.04 \u00e7eyreklik temett\u00fc kuruldu<\/li>\n<li>1923: Diyabet tedavisini d\u00f6n\u00fc\u015ft\u00fcren ins\u00fclin \u00fcretiminin geni\u015flemesinin ard\u0131ndan ilk b\u00fcy\u00fck temett\u00fc art\u0131\u015f\u0131 (+%45)<\/li>\n<li>1972: Modern temett\u00fc \u00e7er\u00e7evesini olu\u015fturan $0.26 hisse ba\u015f\u0131na \u00e7eyreklik temett\u00fc \u00f6deme yap\u0131s\u0131 uyguland\u0131<\/li>\n<li>1995: Kazan\u00e7 dalgalanmalar\u0131na bak\u0131lmaks\u0131z\u0131n y\u0131ll\u0131k %5-7 hedeflenen art\u0131\u015flarla ilerici temett\u00fc politikas\u0131 benimsendi<\/li>\n<li>2009: 62 S&amp;P 500 \u015firketinin temett\u00fcleri tamamen kald\u0131rd\u0131\u011f\u0131 k\u00fcresel mali kriz s\u0131ras\u0131nda $1.96 y\u0131ll\u0131k temett\u00fc korundu<\/li>\n<li>2018: Alt\u0131 y\u0131l \u00fcst \u00fcste %10&#8217;u a\u015fan y\u0131ll\u0131k art\u0131\u015flarla h\u0131zland\u0131r\u0131lm\u0131\u015f temett\u00fc b\u00fcy\u00fcme a\u015famas\u0131 ba\u015flad\u0131<\/li>\n<li>2023: 1990&#8217;dan bu yana %966 art\u0131\u015f\u0131 temsil eden $4.52 y\u0131ll\u0131k \u00f6deme ile enflasyon oran\u0131n\u0131 a\u015fan temett\u00fc b\u00fcy\u00fcmesinin 9. y\u0131l\u0131na ula\u015f\u0131ld\u0131<\/li>\n<\/ul>\n<p>Bu tarihsel perspektif, ekonomik durgunluklar s\u0131ras\u0131nda \u015firketin yakla\u015f\u0131m\u0131n\u0131 de\u011ferlendirirken kritik bir ba\u011flam sa\u011flar. 2008 mali krizi s\u0131ras\u0131nda, 62 S&amp;P 500 \u015firketi temett\u00fcleri tamamen kald\u0131r\u0131rken ve di\u011fer 145&#8217;i \u00f6demeleri azalt\u0131rken, Eli Lilly yaln\u0131zca $1.96 y\u0131ll\u0131k temett\u00fcs\u00fcn\u00fc korumakla kalmad\u0131, ertesi y\u0131l $2.06&#8217;ya \u00e7\u0131kard\u0131. Benzer \u015fekilde, COVID-19 pandemisi s\u0131ras\u0131nda, \u015firket yaln\u0131zca temett\u00fc b\u00fcy\u00fcmesini korumakla kalmad\u0131, ayn\u0131 zamanda y\u0131ll\u0131k %15&#8217;e h\u0131zland\u0131rarak benzeri g\u00f6r\u00fclmemi\u015f piyasa karga\u015fas\u0131 ortas\u0131nda yat\u0131r\u0131mc\u0131 g\u00fcvenini peki\u015ftirdi.<\/p>\n<h3>Temett\u00fc B\u00fcy\u00fcme E\u011frisi Analizi<\/h3>\n<p>Lly hisse temett\u00fcs\u00fcn\u00fcn b\u00fcy\u00fcme e\u011frisi, uzun vadeli gelir arayan yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6nemli kal\u0131plar ortaya koyuyor. Son on y\u0131lda, Lilly temett\u00fcs\u00fcn\u00fc yakla\u015f\u0131k %13.8 bile\u015fik y\u0131ll\u0131k b\u00fcy\u00fcme oran\u0131nda art\u0131rarak hem enflasyonu (%2.7) hem de ila\u00e7 sekt\u00f6r\u00fc ortalamas\u0131n\u0131 (%7.2) \u00f6nemli \u00f6l\u00e7\u00fcde a\u015ft\u0131. Bu temett\u00fc b\u00fcy\u00fcmesindeki h\u0131zlanma, Trulicity, Verzenio, Mounjaro ve Donanemab gibi blokbaster ila\u00e7lar\u0131n ba\u015far\u0131l\u0131 ticarile\u015ftirilmesiyle \u00e7ak\u0131\u015f\u0131yor ve yenilik, gelir b\u00fcy\u00fcmesi ve hissedar getirilerinin erdemli bir d\u00f6ng\u00fcs\u00fcn\u00fc yarat\u0131yor.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Zaman D\u00f6nemi<\/th>\n<th>Temett\u00fc CAGR<\/th>\n<th>Sekt\u00f6r Ortalamas\u0131<\/th>\n<th>S&amp;P 500 Ortalamas\u0131<\/th>\n<th>\u00dcst\u00fcn Performans<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>5 Y\u0131l (2019-2024)<\/td>\n<td>%15.2<\/td>\n<td>%8.1<\/td>\n<td>%5.9<\/td>\n<td>+%9.3 puan<\/td>\n<\/tr>\n<tr>\n<td>10 Y\u0131l (2014-2024)<\/td>\n<td>%13.8<\/td>\n<td>%7.2<\/td>\n<td>%6.3<\/td>\n<td>+%7.5 puan<\/td>\n<\/tr>\n<tr>\n<td>20 Y\u0131l (2004-2024)<\/td>\n<td>%9.7<\/td>\n<td>%6.5<\/td>\n<td>%5.8<\/td>\n<td>+%3.9 puan<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Pocket Option&#8217;\u0131n \u00f6zel Temett\u00fc B\u00fcy\u00fcme Analiz Arac\u0131&#8217;n\u0131 kullanan deneyimli yat\u0131r\u0131mc\u0131lar, Lilly&#8217;nin temett\u00fc b\u00fcy\u00fcme yolculu\u011funda \u00fc\u00e7 farkl\u0131 d\u00f6n\u00fcm noktas\u0131 belirlediler. 2018-2024 d\u00f6nemi, y\u0131ll\u0131k art\u0131\u015flar\u0131n s\u00fcrekli olarak %10&#8217;u a\u015ft\u0131\u011f\u0131 \u00f6zellikle agresif bir b\u00fcy\u00fcme a\u015famas\u0131n\u0131 temsil ediyor. Bu h\u0131zlanma, serbest nakit ak\u0131\u015f\u0131 metriklerinin iyile\u015fmesi (2018&#8217;de $4.1B&#8217;den 2023&#8217;te $8.9B&#8217;ye) ve bor\u00e7-EBITDA oranlar\u0131n\u0131n d\u00fc\u015fmesi (2.3x&#8217;den 1.4x&#8217;e) ile \u00e7ak\u0131\u015f\u0131yor ve \u00f6ng\u00f6r\u00fclebilir gelecekte hissedar getirilerinde s\u00fcrd\u00fcr\u00fclebilir bir ivme oldu\u011funu g\u00f6steriyor.<\/p>\n<h2>LLY Hisse Fiyat\u0131 Temett\u00fc Yat\u0131r\u0131mlar\u0131na Stratejik Yakla\u015f\u0131mlar<\/h2>\n<p>Lly hisse temett\u00fc yat\u0131r\u0131mlar\u0131 i\u00e7in kazanan bir strateji olu\u015fturmak, %0.75&#8217;lik aldat\u0131c\u0131 derecede m\u00fctevaz\u0131 getirinin \u00f6tesine bakmay\u0131 ve S&amp;P 500 \u015firketlerinin %93&#8217;\u00fcn\u00fc a\u015fan %15.2 y\u0131ll\u0131k temett\u00fc b\u00fcy\u00fcme oran\u0131n\u0131 ortaya \u00e7\u0131karmay\u0131 gerektirir. Lly hisse fiyat\u0131 temett\u00fc ili\u015fkisi, farkl\u0131 yat\u0131r\u0131mc\u0131 profilleri i\u00e7in \u00e7e\u015fitli stratejik giri\u015f noktalar\u0131 sunar. Temett\u00fc hisse senetlerini sat\u0131n almadan \u00f6nce getiri art\u0131\u015flar\u0131n\u0131 beklemeyi \u00f6neren geleneksel bilgelik aksine, Eli Lilly, fiyat art\u0131\u015f\u0131n\u0131n s\u00fcrekli olarak temett\u00fc b\u00fcy\u00fcmesini a\u015ft\u0131\u011f\u0131 benzersiz bir durum sunar ve artan mutlak \u00f6demelere ra\u011fmen azalan bir getiri paradoksu yarat\u0131r.<\/p>\n<p>Pocket Option&#8217;\u0131n geli\u015fmi\u015f teknik analiz ara\u00e7lar\u0131n\u0131 kullanan yat\u0131r\u0131mc\u0131lar, Lilly&#8217;nin temett\u00fc program\u0131ndan maksimum getiri elde etmek i\u00e7in birka\u00e7 etkili yakla\u015f\u0131m belirlediler:<\/p>\n<ul>\n<li>Piyasa dalgalanma d\u00f6nemlerinde dolar-maliyet ortalamas\u0131 yaparak farkl\u0131 fiyat noktalar\u0131nda pozisyonlar biriktirmek, potansiyel olarak genel getiriyi %0.3-0.5 puan art\u0131rabilir<\/li>\n<li>Biriktirme a\u015famalar\u0131nda getirileri bile\u015fik hale getirmek i\u00e7in temett\u00fc yeniden yat\u0131r\u0131m programlar\u0131 (DRIP&#8217;ler) uygulamak, tarihsel olarak yeniden yat\u0131r\u0131lmayan pozisyonlara kar\u015f\u0131 %2.7 y\u0131ll\u0131k performans eklemi\u015ftir<\/li>\n<li>Tarihsel kal\u0131plara dayal\u0131 olarak ortalama %1.2 ek getiri yakalayarak temett\u00fc duyurular\u0131na fiyat tepkilerini izlerken temett\u00fc tarihinden 14-21 g\u00fcn \u00f6nce stratejik pozisyon olu\u015fturmak<\/li>\n<li>Toplam getiriyi optimize etmek i\u00e7in temett\u00fc odakl\u0131 varl\u0131klar\u0131 (%75) b\u00fcy\u00fcme odakl\u0131 ila\u00e7 hisse senetleriyle (%25) dengelemek, tarihsel olarak saf temett\u00fc stratejilerinden %3.4 daha y\u00fcksek y\u0131ll\u0131k getiri sa\u011flam\u0131\u015ft\u0131r<\/li>\n<li>Temett\u00fc \u00f6deyen pozisyonlardan %4-6 ek gelir elde etmek i\u00e7in Pocket Option gibi platformlarda kapal\u0131 al\u0131m opsiyon stratejileri kullanmak, potansiyel y\u00fckseli\u015fin %70-80&#8217;ine maruz kalmay\u0131 s\u00fcrd\u00fcrmek<\/li>\n<\/ul>\n<p>Lly hisse fiyat\u0131 temett\u00fc korelasyonunun analizi, \u015firketin bir\u00e7ok rakibine g\u00f6re temett\u00fc tarihleri etraf\u0131nda daha az fiyat dalgalanmas\u0131 ya\u015fad\u0131\u011f\u0131n\u0131 ortaya koyuyor. Bu istikrar, tahmin edilebilir nakit ak\u0131\u015flar\u0131 arayan gelir odakl\u0131 portf\u00f6yler i\u00e7in \u00f6zellikle uygundur. \u0130leri d\u00fczey yat\u0131r\u0131mc\u0131lar ayr\u0131ca Lilly&#8217;nin temett\u00fc duyurular\u0131n\u0131n genellikle azalan volatilite d\u00f6nemlerinden \u00f6nce geldi\u011fini ve 30-45 DTE (vade dolum g\u00fcnleri) kapal\u0131 al\u0131m opsiyonlar\u0131 ile optimal risk ayarl\u0131 getiriler sunan gelir stratejileri i\u00e7in f\u0131rsatlar yaratt\u0131\u011f\u0131n\u0131 belirttiler.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Yat\u0131r\u0131m Stratejisi<\/th>\n<th>Risk Profili<\/th>\n<th>Gelir Potansiyeli<\/th>\n<th>Sermaye De\u011ferlenmesi<\/th>\n<th>Zaman Ufku<\/th>\n<th>Optimal Da\u011f\u0131l\u0131m<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Saf Gelir Odakl\u0131<\/td>\n<td>D\u00fc\u015f\u00fck-Orta<\/td>\n<td>Orta (%3-5)<\/td>\n<td>Orta (%7-9)<\/td>\n<td>5+ y\u0131l<\/td>\n<td>Portf\u00f6y\u00fcn %15-25&#8217;i<\/td>\n<\/tr>\n<tr>\n<td>B\u00fcy\u00fcme &amp; Gelir Hibrit<\/td>\n<td>Orta<\/td>\n<td>Orta (%2-4)<\/td>\n<td>Y\u00fcksek (%12-15)<\/td>\n<td>7+ y\u0131l<\/td>\n<td>Portf\u00f6y\u00fcn %30-40&#8217;\u0131<\/td>\n<\/tr>\n<tr>\n<td>DRIP Birikimi<\/td>\n<td>Orta<\/td>\n<td>D\u00fc\u015f\u00fck Ba\u015flang\u0131\u00e7 (%0.5-1)\/Y\u00fcksek Sonra (%5-7)<\/td>\n<td>Y\u00fcksek (%13-17)<\/td>\n<td>10+ y\u0131l<\/td>\n<td>Portf\u00f6y\u00fcn %50-60&#8217;\u0131<\/td>\n<\/tr>\n<tr>\n<td>Opsiyonlarla Art\u0131r\u0131lm\u0131\u015f Gelir<\/td>\n<td>Orta-Y\u00fcksek<\/td>\n<td>Y\u00fcksek (%5-8)<\/td>\n<td>Orta (%6-9)<\/td>\n<td>3+ y\u0131l<\/td>\n<td>Portf\u00f6y\u00fcn %10-15&#8217;i<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2>K\u0131yaslama Analizi: lly hisse temett\u00fcs\u00fc vs. \u0130la\u00e7 Sekt\u00f6r\u00fc Rakipleri<\/h2>\n<p>Eli Lilly&#8217;nin temett\u00fc program\u0131n\u0131n de\u011fer \u00f6nerisini tam olarak anlamak i\u00e7in, ila\u00e7 sekt\u00f6r\u00fc rakiplerine kar\u015f\u0131 bir k\u0131yaslama analizi yapmak \u00f6nemlidir. Bu ba\u011flam, yat\u0131r\u0131mc\u0131lar\u0131n lly hisse temett\u00fcs\u00fcn\u00fcn sekt\u00f6rdeki alternatif yat\u0131r\u0131mlara k\u0131yasla \u00fcst\u00fcn risk ayarl\u0131 getiriler sunup sunmad\u0131\u011f\u0131n\u0131 belirlemelerine yard\u0131mc\u0131 olur. Lilly&#8217;nin mevcut getirisi (%0.75) Pfizer (%5.87) veya AbbVie (%3.58) ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda m\u00fctevaz\u0131 g\u00f6r\u00fcnse de, kapsaml\u0131 bir de\u011ferlendirme, basit getiri kar\u015f\u0131la\u015ft\u0131rmalar\u0131n\u0131 a\u015fan birka\u00e7 belirgin avantaj\u0131 ortaya koyuyor.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>\u015eirket<\/th>\n<th>Mevcut Getiri<\/th>\n<th>5 Y\u0131ll\u0131k Temett\u00fc CAGR<\/th>\n<th>\u00d6deme Oran\u0131<\/th>\n<th>Temett\u00fc G\u00fcvenlik Skoru<\/th>\n<th>10 Y\u0131ll\u0131k Toplam Getiri<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Eli Lilly (LLY)<\/td>\n<td>%0.75<\/td>\n<td>%15.2<\/td>\n<td>%42.1<\/td>\n<td>87\/100<\/td>\n<td>+%842<\/td>\n<\/tr>\n<tr>\n<td>Johnson &amp; Johnson (JNJ)<\/td>\n<td>%3.21<\/td>\n<td>%5.9<\/td>\n<td>%68.7<\/td>\n<td>91\/100<\/td>\n<td>+%132<\/td>\n<\/tr>\n<tr>\n<td>Pfizer (PFE)<\/td>\n<td>%5.87<\/td>\n<td>%3.2<\/td>\n<td>%89.4<\/td>\n<td>72\/100<\/td>\n<td>+%37<\/td>\n<\/tr>\n<tr>\n<td>Merck (MRK)<\/td>\n<td>%2.67<\/td>\n<td>%8.7<\/td>\n<td>%55.2<\/td>\n<td>84\/100<\/td>\n<td>+%213<\/td>\n<\/tr>\n<tr>\n<td>AbbVie (ABBV)<\/td>\n<td>%3.58<\/td>\n<td>%9.2<\/td>\n<td>%63.1<\/td>\n<td>76\/100<\/td>\n<td>+%368<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Pocket Option&#8217;daki finansal analistler, bu k\u0131yaslama analizinden \u00fc\u00e7 \u00f6nemli g\u00f6zlem vurguluyor. \u0130lk olarak, Lilly, b\u00fcy\u00fck ila\u00e7 temett\u00fc \u00f6deyenler aras\u0131nda en d\u00fc\u015f\u00fck mevcut getiriyi sunarken, en y\u00fcksek b\u00fcy\u00fcme oran\u0131n\u0131 \u00f6nemli bir farkla g\u00f6steriyor (en yak\u0131n rakibin %6.0 puan \u00fczerinde). Bu, daha uzun zaman ufuklar\u0131na sahip yat\u0131r\u0131mc\u0131lar\u0131n, daha d\u00fc\u015f\u00fck ba\u015flang\u0131\u00e7 getirisine ra\u011fmen nihayetinde daha y\u00fcksek mutlak temett\u00fcler alabilece\u011fini g\u00f6steriyor. \u0130kinci olarak, Lilly, rakipleri aras\u0131nda en muhafazakar \u00f6deme oran\u0131n\u0131 koruyor (%42.1, sekt\u00f6r ortalamas\u0131 %63.4&#8217;e kar\u015f\u0131), bu da gelecekteki temett\u00fc art\u0131\u015flar\u0131 i\u00e7in daha fazla kapasite ve kazan\u00e7 dalgalanmalar\u0131na kar\u015f\u0131 daha az savunmas\u0131zl\u0131k g\u00f6steriyor.<\/p>\n<p>\u00dc\u00e7\u00fcnc\u00fc ve belki de en \u00f6nemlisi: Lilly&#8217;nin ola\u011fan\u00fcst\u00fc toplam getiri profili, her b\u00fcy\u00fck zaman diliminde ila\u00e7 sekt\u00f6r\u00fcndeki rakiplerini g\u00f6lgede b\u0131rak\u0131yor. Temett\u00fc gelirini hisse fiyat\u0131 art\u0131\u015f\u0131yla birle\u015ftirirken, Lilly, en yak\u0131n rakibi AbbVie&#8217;yi son on y\u0131lda %474 puanla geride b\u0131rakt\u0131. Bu performans, yaln\u0131zca mevcut getiriye odaklanman\u0131n potansiyel s\u0131n\u0131rlamalar\u0131n\u0131, temett\u00fc b\u00fcy\u00fcmesi ve sermaye de\u011ferlenmesi potansiyelini dikkate almadan dramatik bir \u015fekilde g\u00f6steriyor &#8211; Pocket Option gibi platformlarla uzun vadeli gelir portf\u00f6yleri olu\u015fturan yat\u0131r\u0131mc\u0131lar i\u00e7in kritik bir i\u00e7g\u00f6r\u00fc.<\/p>\n<h2>Gelecek G\u00f6r\u00fcn\u00fcm\u00fc: lly hisse temett\u00fc Y\u00f6r\u00fcngesini Tahmin Etmek<\/h2>\n<p>2030 y\u0131l\u0131na kadar lly hisse temett\u00fc y\u00f6r\u00fcngesini tahmin etmek, \u00fc\u00e7 kritik g\u00f6stergenin analizini gerektirir: boru hatt\u0131 ticarile\u015ftirme zaman \u00e7izelgeleri, marj geni\u015fleme f\u0131rsatlar\u0131 ve Ocak 2024 yat\u0131r\u0131mc\u0131 konferans\u0131nda a\u00e7\u0131klanan y\u00f6netimin a\u00e7\u0131k temett\u00fc b\u00fcy\u00fcme hedefleri. \u015eirketin obezite, diyabet ve Alzheimer hastal\u0131\u011f\u0131 gibi y\u00fcksek b\u00fcy\u00fcme g\u00f6steren tedavi alanlar\u0131ndaki sa\u011flam boru hatt\u0131, gelecekteki nakit ak\u0131\u015f\u0131 \u00fcretimi ve temett\u00fc deste\u011fi i\u00e7in sa\u011flam bir temel sa\u011flar.<\/p>\n<h3>Boru Hatt\u0131n\u0131n Temett\u00fc S\u00fcrd\u00fcr\u00fclebilirli\u011fine Etkisi<\/h3>\n<p>Eli Lilly&#8217;nin ara\u015ft\u0131rma boru hatt\u0131, ila\u00e7 end\u00fcstrisindeki en umut verici boru hatlar\u0131ndan birini temsil ediyor ve \u00e7e\u015fitli a\u015famalarda klinik geli\u015ftirmede 43 molek\u00fcl bulunuyor. \u00d6zellikle, diyabet ve obezite i\u00e7in \u015firketin GLP-1 resept\u00f6r agonistleri, ola\u011fan\u00fcst\u00fc ticari ba\u015far\u0131 g\u00f6stermi\u015f ve hala \u00f6nemli bir b\u00fcy\u00fcme potansiyeline sahip. Pocket Option&#8217;\u0131n ara\u015ft\u0131rma ekibinden finansal projeksiyonlar, bu tedavilerin tek ba\u015f\u0131na, en az 2028&#8217;e kadar \u00e7ift haneli temett\u00fc b\u00fcy\u00fcmesini desteklemek i\u00e7in yeterli ek gelir \u00fcretebilece\u011fini \u00f6ne s\u00fcr\u00fcyor, ba\u015fka hi\u00e7bir boru hatt\u0131 varl\u0131\u011f\u0131 ticarile\u015fmese bile.<\/p>\n<ul>\n<li>Orta a\u015fama boru hatt\u0131, y\u0131ll\u0131k 42 milyar dolar\u0131 a\u015fan birle\u015fik zirve sat\u0131\u015f potansiyeline sahip, birden fazla tedavi alan\u0131nda 17 potansiyel blokbaster aday\u0131 i\u00e7eriyor<\/li>\n<li>Obezite (Zepbound) ve Alzheimer tedavilerinde (Kisunla) son d\u00fczenleyici onaylar, 2033&#8217;ten \u00f6nce s\u0131n\u0131rl\u0131 patent s\u00fcresi dolma riskiyle \u00e7ok y\u0131ll\u0131k gelir g\u00f6r\u00fcn\u00fcrl\u00fc\u011f\u00fc sa\u011fl\u0131yor<\/li>\n<li>Y\u00fcksek marjl\u0131 \u00f6zel ila\u00e7lara odaklanma, nakit ak\u0131\u015f\u0131 \u00fcretimini destekliyor ve br\u00fct marjlar 2020&#8217;den bu yana %76.3&#8217;ten %79.8&#8217;e geni\u015fliyor<\/li>\n<li>\u00d6nceki on y\u0131llara k\u0131yasla patent u\u00e7urumlar\u0131na daha az maruz kalma, kazan\u00e7 \u00f6ng\u00f6r\u00fclebilirli\u011fini art\u0131r\u0131yor ve Verzenio&#8217;ya kadar (2029) b\u00fcy\u00fck patent s\u00fcresi dolmas\u0131 yok<\/li>\n<li>\u00d6n\u00fcm\u00fczdeki \u00fc\u00e7 y\u0131l i\u00e7inde kar marjlar\u0131n\u0131 %2.4 puan art\u0131rmas\u0131 beklenen operasyonel verimlilik giri\u015fimleri, gelir art\u0131\u015f\u0131 gerektirmeden ek temett\u00fc kapasitesi yarat\u0131yor<\/li>\n<\/ul>\n<p>Bu fakt\u00f6rleri i\u00e7eren kapsaml\u0131 finansal modellemeye dayanarak, analistler Eli Lilly&#8217;nin \u00f6n\u00fcm\u00fczdeki be\u015f y\u0131l boyunca y\u0131ll\u0131k %12-16 aras\u0131nda temett\u00fc b\u00fcy\u00fcme oranlar\u0131n\u0131 s\u00fcrd\u00fcrece\u011fini \u00f6ng\u00f6r\u00fcyor. Bu g\u00f6r\u00fcn\u00fcm, \u015firketin muhafazakar \u00f6deme oran\u0131, m\u00fctevaz\u0131 bor\u00e7 seviyeleriyle g\u00fc\u00e7l\u00fc bilan\u00e7osu (sekt\u00f6r ortalamas\u0131 2.2x&#8217;e kar\u015f\u0131 1.4x bor\u00e7-EBITDA) ve son yat\u0131r\u0131mc\u0131 ileti\u015fimlerinde a\u00e7\u0131k\u00e7a ifade edilen ilerici temett\u00fc politikalar\u0131na olan ba\u011fl\u0131l\u0131\u011f\u0131 taraf\u0131ndan desteklenmektedir.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Y\u0131l<\/th>\n<th>Tahmini Y\u0131ll\u0131k Temett\u00fc<\/th>\n<th>Tahmini B\u00fcy\u00fcme Oran\u0131<\/th>\n<th>Tahmini \u00d6deme Oran\u0131<\/th>\n<th>Tahmini Getiri Aral\u0131\u011f\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>2025<\/td>\n<td>$5.98<\/td>\n<td>%15.0<\/td>\n<td>%41.8<\/td>\n<td>%0.65-0.80<\/td>\n<\/tr>\n<tr>\n<td>2026<\/td>\n<td>$6.82<\/td>\n<td>%14.0<\/td>\n<td>%40.7<\/td>\n<td>%0.60-0.75<\/td>\n<\/tr>\n<tr>\n<td>2027<\/td>\n<td>$7.71<\/td>\n<td>%13.0<\/td>\n<td>%39.5<\/td>\n<td>%0.55-0.70<\/td>\n<\/tr>\n<tr>\n<td>2028<\/td>\n<td>$8.64<\/td>\n<td>%12.0<\/td>\n<td>%38.9<\/td>\n<td>%0.50-0.65<\/td>\n<\/tr>\n<tr>\n<td>2029<\/td>\n<td>$9.59<\/td>\n<td>%11.0<\/td>\n<td>%38.2<\/td>\n<td>%0.45-0.60<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2>Temett\u00fc Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Pratik Hususlar<\/h2>\n<p>Temel analizlerin \u00f6tesinde, pratik uygulama hususlar\u0131 temett\u00fc yat\u0131r\u0131mlar\u0131ndan elde edilen getirileri optimize etmede \u00f6nemli bir rol oynar. \u00d6zellikle lly hisse fiyat\u0131 temett\u00fcs\u00fcyle ilgilenenler i\u00e7in, birka\u00e7 pratik strateji genel performans\u0131 art\u0131rabilir. Pocket Option&#8217;\u0131 kullanan yat\u0131r\u0131mc\u0131lar, Eli Lilly&#8217;nin temett\u00fc program\u0131 etraf\u0131nda \u00f6nemli gelir \u00fcreten portf\u00f6yler olu\u015fturmak i\u00e7in bu yakla\u015f\u0131mlar\u0131 ba\u015far\u0131yla uygulad\u0131lar.<\/p>\n<p>Vergi verimlili\u011fi, temett\u00fc yat\u0131r\u0131m\u0131n\u0131n kritik ancak genellikle g\u00f6z ard\u0131 edilen bir y\u00f6n\u00fcn\u00fc temsil eder. Bir yat\u0131r\u0131mc\u0131n\u0131n vergi yarg\u0131 yetkisi ve hesap yap\u0131s\u0131na ba\u011fl\u0131 olarak, Lilly gibi temett\u00fc hisse senetlerinin stratejik konumland\u0131r\u0131lmas\u0131, vergi sonras\u0131 getirileri \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilir. ABD&#8217;li yat\u0131r\u0131mc\u0131lar i\u00e7in, temett\u00fc \u00f6deyen hisse senetlerini IRA&#8217;lar veya 401(k)&#8217;ler gibi vergi avantajl\u0131 hesaplarda tutmak, temett\u00fc gelirindeki vergi y\u00fck\u00fcml\u00fcl\u00fcklerini erteleyebilir veya azaltabilir. Uluslararas\u0131 yat\u0131r\u0131mc\u0131lar, temett\u00fc portf\u00f6ylerini yap\u0131land\u0131r\u0131rken yerel vergi anla\u015fmalar\u0131n\u0131 ve stopaj etkilerini benzer \u015fekilde dikkate almal\u0131d\u0131r.<\/p>\n<p>Temett\u00fc yeniden yat\u0131r\u0131m zamanlamas\u0131 da dikkatli bir de\u011ferlendirme gerektirir. Otomatik temett\u00fc yeniden yat\u0131r\u0131m planlar\u0131 kolayl\u0131k sunarken, stratejik yat\u0131r\u0131mc\u0131lar fiyat dalgalanmalar\u0131ndan yararlanmak i\u00e7in manuel yeniden yat\u0131r\u0131m\u0131 tercih edebilir. Lilly&#8217;nin tarihsel fiyat kal\u0131plar\u0131n\u0131n analizi, hissenin genellikle her \u00e7eyre\u011fin ilk ay\u0131nda m\u00fctevaz\u0131 bir zay\u0131fl\u0131k ya\u015fad\u0131\u011f\u0131n\u0131 ve otomatik programlar\u0131n fiyat ne olursa olsun hemen yeniden yat\u0131rd\u0131\u011f\u0131na k\u0131yasla daha uygun yeniden yat\u0131r\u0131m f\u0131rsatlar\u0131 sunabilece\u011fini ortaya koyuyor.<\/p>\n<div class=\"table-container\">\n<table>\n<thead>\n<tr>\n<th>Hususlar<\/th>\n<th>Getiriler \u00dczerindeki Etki<\/th>\n<th>Uygulama Karma\u015f\u0131kl\u0131\u011f\u0131<\/th>\n<th>\u00d6nerilen<\/th>\n<th>Potansiyel Getiri Art\u0131\u015f\u0131<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Vergi Verimli Yerle\u015ftirme<\/td>\n<td>Y\u00fcksek<\/td>\n<td>Orta<\/td>\n<td>T\u00fcm Yat\u0131r\u0131mc\u0131lar<\/td>\n<td>+%0.8-1.7 y\u0131ll\u0131k<\/td>\n<\/tr>\n<tr>\n<td>Stratejik Yeniden Yat\u0131r\u0131m<\/td>\n<td>Orta<\/td>\n<td>Y\u00fcksek<\/td>\n<td>Aktif Yat\u0131r\u0131mc\u0131lar<\/td>\n<td>+%0.4-0.9 y\u0131ll\u0131k<\/td>\n<\/tr>\n<tr>\n<td>Pozisyon Boyutland\u0131rma<\/td>\n<td>Y\u00fcksek<\/td>\n<td>Orta<\/td>\n<td>T\u00fcm Yat\u0131r\u0131mc\u0131lar<\/td>\n<td>Risk azaltma \u00f6ncelikli<\/td>\n<\/tr>\n<tr>\n<td>Temett\u00fc Yakalama<\/td>\n<td>D\u00fc\u015f\u00fck-Orta<\/td>\n<td>\u00c7ok Y\u00fcksek<\/td>\n<td>Geli\u015fmi\u015f T\u00fcccarlar<\/td>\n<td>+%0.2-0.6 y\u0131ll\u0131k<\/td>\n<\/tr>\n<tr>\n<td>Opsiyonlarla Art\u0131rma<\/td>\n<td>Orta-Y\u00fcksek<\/td>\n<td>Y\u00fcksek<\/td>\n<td>Deneyimli Yat\u0131r\u0131mc\u0131lar<\/td>\n<td>+%2.5-4.0 y\u0131ll\u0131k<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Portf\u00f6y olu\u015fturma, ba\u015fka bir kritik hususu temsil eder. Eli Lilly \u00e7ekici temett\u00fc \u00f6zellikleri sunarken, yo\u011funla\u015fma riski bir endi\u015fe kayna\u011f\u0131 olmaya devam ediyor. Pocket Option&#8217;daki yat\u0131r\u0131m profesyonelleri, y\u00fcksek g\u00fcvenli temett\u00fc hisse senetleri i\u00e7in bile bireysel pozisyonlar\u0131 toplam portf\u00f6y de\u011ferinin %3-5&#8217;i ile s\u0131n\u0131rlamay\u0131 genellikle \u00f6nerir. Bu yakla\u015f\u0131m, ola\u011fan\u00fcst\u00fc temett\u00fc b\u00fcy\u00fct\u00fcc\u00fcleri olan Lilly gibi \u015firketlere anlaml\u0131 bir maruz kalma sa\u011flarken, gelir hedeflerini ihtiyatl\u0131 risk y\u00f6netimi ile dengeler.<\/p>\n    <div class=\"po-container po-container_width_article\">\n        <a href=\"\/en\/quick-start\/\" class=\"po-line-banner po-article-page__line-banner\">\n            <svg class=\"svg-image po-line-banner__logo\" fill=\"currentColor\" width=\"auto\" height=\"auto\"\n                 aria-hidden=\"true\">\n                <use href=\"#svg-img-logo-white\"><\/use>\n            <\/svg>\n            <span class=\"po-line-banner__btn\">Start Trading<\/span>\n        <\/a>\n    <\/div>\n    \n<h2>Sonu\u00e7: lly hisse temett\u00fcs\u00fcne Yakla\u015f\u0131m\u0131n\u0131z\u0131 Optimize Etmek<\/h2>\n<p>Lly hisse temett\u00fcs\u00fc, yat\u0131r\u0131mc\u0131n\u0131n ideal senaryosunu \u00f6rnekler: %0.75&#8217;lik m\u00fctevaz\u0131 mevcut getiri, sekt\u00f6r lideri %15.2 y\u0131ll\u0131k b\u00fcy\u00fcme ile birle\u015ferek hem an\u0131nda gelir hem de \u00fcstel uzun vadeli bile\u015fik potansiyel sunar. Bir\u00e7ok yat\u0131r\u0131mc\u0131, Lilly&#8217;yi y\u00fczeysel olarak d\u00fc\u015f\u00fck ba\u015fl\u0131k getirisi nedeniyle g\u00f6z ard\u0131 ederken, sofistike temett\u00fc avc\u0131lar\u0131, bu aldat\u0131c\u0131 derecede m\u00fctevaz\u0131 say\u0131lar\u0131n alt\u0131nda g\u00fc\u00e7l\u00fc bir servet olu\u015fturma motorunu tan\u0131r.<\/p>\n<p>Eli Lilly&#8217;nin temett\u00fc program\u0131n\u0131 portf\u00f6ylerine dahil etmek isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in kapsaml\u0131 analizimizden \u00fc\u00e7 anahtar ilke ortaya \u00e7\u0131k\u0131yor. \u0130lk olarak, \u00f6zellikle Lilly&#8217;nin ola\u011fan\u00fcst\u00fc nakit ak\u0131\u015f\u0131 \u00fcretim yetenekleri ve %15.2 CAGR ile \u015firketler i\u00e7in mevcut getiriyi izole olarak de\u011fil, temett\u00fc b\u00fcy\u00fcme y\u00f6r\u00fcngesine odaklan\u0131n. \u0130kincisi, temett\u00fc geliri ile sermaye de\u011ferlenmesi potansiyeli aras\u0131ndaki tamamlay\u0131c\u0131 ili\u015fkiyi d\u00fc\u015f\u00fcn\u00fcn &#8211; Lilly&#8217;nin %842 on y\u0131ll\u0131k toplam getirisi, daha y\u00fcksek getirili alternatifleri dramatik bir \u015fekilde geride b\u0131rak\u0131yor. \u00dc\u00e7\u00fcnc\u00fcs\u00fc, stratejik yakla\u015f\u0131mlar uygulay\u0131n, pozisyon olu\u015fturma, yeniden yat\u0131r\u0131m ve vergi y\u00f6netimi, tam piyasa d\u00f6ng\u00fcleri boyunca vergi sonras\u0131 getirileri optimize etmek i\u00e7in.<\/p>\n<p>\u0130la\u00e7 sekt\u00f6r\u00fc h\u0131zla geli\u015fmeye devam ediyor, \u00e7\u0131\u011f\u0131r a\u00e7an yenilikler yeni pazar f\u0131rsatlar\u0131 yarat\u0131rken, d\u00fczenleyici ve fiyatland\u0131rma bask\u0131lar\u0131 karma\u015f\u0131k zorluklar getiriyor. Bu dinamik ortamda, Eli Lilly, y\u00fcksek b\u00fcy\u00fcme g\u00f6steren tedavi alanlar\u0131n\u0131n \u00f6n saflar\u0131nda yer al\u0131rken, hissedar getirilerine olan y\u00fczy\u0131l\u0131 a\u015fk\u0131n ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 s\u00fcrd\u00fcrerek ola\u011fan\u00fcst\u00fc uyum sa\u011flama ve stratejik vizyon sergilemi\u015ftir. Bu ortamda gezinirken, Pocket Option gibi platformlar, temett\u00fc s\u00fcrd\u00fcr\u00fclebilirli\u011fini de\u011ferlendirmek ve kapsaml\u0131 bir portf\u00f6y stratejisi i\u00e7inde yat\u0131r\u0131m zamanlamas\u0131n\u0131 optimize etmek i\u00e7in de\u011ferli analitik ara\u00e7lar sa\u011flar.<\/p>\n<p>Kendi ila\u00e7 temett\u00fc yat\u0131r\u0131m yakla\u015f\u0131m\u0131n\u0131z\u0131 geli\u015ftirirken, ba\u015far\u0131l\u0131 gelir stratejilerinin yaln\u0131zca ba\u015fl\u0131k getirilerini kovalamak yerine, an\u0131nda getiri gereksinimlerini uzun vadeli b\u00fcy\u00fcme potansiyeli ile dengeledi\u011fini unutmay\u0131n. Lly hisse temett\u00fcs\u00fc, m\u00fctevaz\u0131 ba\u015flang\u0131\u00e7 getirileri sunar ancak diyabet, obezite ve Alzheimer tedavilerindeki temel i\u015f g\u00fcc\u00fcyle desteklenen ola\u011fan\u00fcst\u00fc b\u00fcy\u00fcme beklentileri sunar. Bu analizde \u00f6zetlenen kan\u0131ta dayal\u0131 ilkeleri ve stratejileri uygulayarak, yat\u0131r\u0131mc\u0131lar, benzersiz finansal hedefleri ve risk parametreleriyle uyumlu sofistike ila\u00e7 temett\u00fc portf\u00f6yleri olu\u015fturabilirler.<\/p>\n<\/div>\n"},"faq":[{"question":"Eli Lilly (LLY) hissesinin mevcut temett\u00fc getirisi nedir?","answer":"Nisan 2025 itibar\u0131yla, Eli Lilly'nin temett\u00fc getirisi yakla\u015f\u0131k %0,75 seviyesindedir. Bu g\u00f6r\u00fcn\u00fc\u015fte m\u00fctevaz\u0131 getiri, yetersiz temett\u00fc \u00f6demelerinden ziyade ola\u011fan\u00fcst\u00fc hisse senedi fiyat\u0131 art\u0131\u015f\u0131n\u0131 yans\u0131tmaktad\u0131r. Pfizer gibi rakipler daha y\u00fcksek getiriler sunarken (%5,87), Lilly, mutlak temett\u00fc miktar\u0131n\u0131 y\u0131ll\u0131k %15,2 gibi sekt\u00f6r lideri bir oranda s\u00fcrekli olarak art\u0131rm\u0131\u015ft\u0131r -- bu oran S&P 500 ortalamas\u0131n\u0131n neredeyse \u00fc\u00e7 kat\u0131d\u0131r. Bu b\u00fcy\u00fcme odakl\u0131 yakla\u015f\u0131m, daha d\u00fc\u015f\u00fck ba\u015fl\u0131k getirisine ra\u011fmen \u00fcst\u00fcn toplam getiriler sa\u011flam\u0131\u015ft\u0131r."},{"question":"Eli Lilly ne s\u0131kl\u0131kla temett\u00fc \u00f6der?","answer":"Eli Lilly, Mart, Haziran, Eyl\u00fcl ve Aral\u0131k aylar\u0131nda genellikle \u00f6demeler yaparak temett\u00fcleri \u00fc\u00e7 ayda bir da\u011f\u0131t\u0131r. Bu \u00fc\u00e7 ayl\u0131k program, 1972'den beri tutarl\u0131 bir \u015fekilde devam etmekte olup, y\u0131l boyunca hissedarlara \u00f6ng\u00f6r\u00fclebilir gelir ak\u0131\u015flar\u0131 sa\u011flamaktad\u0131r. \u015eirket, da\u011f\u0131t\u0131mdan yakla\u015f\u0131k 45 g\u00fcn \u00f6nce kesin \u00f6deme tarihlerini duyurur ve bu bilgilere Eli Lilly'nin yat\u0131r\u0131mc\u0131 ili\u015fkileri portal\u0131 veya Pocket Option'\u0131n temett\u00fc takvimi \u00f6zelli\u011fi gibi finansal platformlar arac\u0131l\u0131\u011f\u0131yla ula\u015f\u0131labilir."},{"question":"Eli Lilly'nin temett\u00fc oran\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda temett\u00fcs\u00fc s\u00fcrd\u00fcr\u00fclebilir mi?","answer":"Eli Lilly'nin temett\u00fcs\u00fc, muhafazakar %42,1'lik \u00f6deme oran\u0131 sayesinde ola\u011fan\u00fcst\u00fc bir s\u00fcrd\u00fcr\u00fclebilirlik sergiliyor -- bu oran hem ila\u00e7 end\u00fcstrisi ortalamas\u0131n\u0131n (%63,4) hem de kendi tarihsel aral\u0131\u011f\u0131n\u0131n olduk\u00e7a alt\u0131nda. Bu disiplinli yakla\u015f\u0131m, kazan\u00e7 dalgalanmalar\u0131 d\u00f6nemlerinde bile temett\u00fc b\u00fcy\u00fcmesi i\u00e7in \u00f6nemli bir kapasite sa\u011flar. Bu s\u00fcrd\u00fcr\u00fclebilirli\u011fi destekleyen unsurlar aras\u0131nda Lilly'nin artan serbest nakit ak\u0131\u015f\u0131 (2023'te 8,9 milyar dolar, 2018'de 4,1 milyar dolardan), g\u00fc\u00e7l\u00fc bilan\u00e7o metrikleri (1,4x bor\u00e7\/EBITDA) ve 2030 sonras\u0131na kadar patent korumas\u0131 olan \u00e7\u0131\u011f\u0131r a\u00e7an ila\u00e7lar yer al\u0131yor."},{"question":"Eli Lilly'nin temett\u00fc b\u00fcy\u00fcmesi, ila\u00e7 end\u00fcstrisindeki rakipleriyle nas\u0131l kar\u015f\u0131la\u015ft\u0131r\u0131l\u0131r?","answer":"Eli Lilly, be\u015f y\u0131ll\u0131k %15,2'lik bile\u015fik y\u0131ll\u0131k b\u00fcy\u00fcme oran\u0131 (CAGR) ile ila\u00e7 end\u00fcstrisinin temett\u00fc b\u00fcy\u00fcme lideri olarak kendini kan\u0131tlam\u0131\u015ft\u0131r -- en yak\u0131n rakibi AbbVie'yi (%9,2) \u00f6nemli \u00f6l\u00e7\u00fcde geride b\u0131rakarak ve sekt\u00f6r ortalamas\u0131n\u0131 (%7,2) ikiye katlayarak. Bu ola\u011fan\u00fcst\u00fc b\u00fcy\u00fcme oran\u0131, Lilly'nin y\u00fcksek k\u00e2r marjl\u0131 tedavi alanlar\u0131na stratejik odaklanmas\u0131n\u0131, operasyonel verimlilik iyile\u015ftirmelerini ve y\u00f6netimin hissedarlara de\u011fer kazand\u0131rma konusundaki a\u00e7\u0131k taahh\u00fcd\u00fcn\u00fc yans\u0131tmaktad\u0131r. Pfizer (%3,2) ve Johnson & Johnson (%5,9) gibi rakipler daha y\u00fcksek ba\u015flang\u0131\u00e7 getirileri sunarken, Lilly'nin b\u00fcy\u00fcme odakl\u0131 yakla\u015f\u0131m\u0131 5 y\u0131ll\u0131k, 10 y\u0131ll\u0131k ve 20 y\u0131ll\u0131k d\u00f6nemlerde \u00fcst\u00fcn toplam getiri sa\u011flam\u0131\u015ft\u0131r."},{"question":"Eli Lilly'den temett\u00fc geliri elde etmek i\u00e7in en iyi strateji nedir?","answer":"Optimal strateji, yat\u0131r\u0131m zaman \u00e7izelgenize ve gelir gereksinimlerinize ba\u011fl\u0131d\u0131r. Maksimum uzun vadeli gelir b\u00fcy\u00fcmesine odaklanan 10+ y\u0131ll\u0131k ufuklara sahip yat\u0131r\u0131mc\u0131lar i\u00e7in, disiplinli bir DRIP (temett\u00fc yeniden yat\u0131r\u0131m plan\u0131) stratejisi uygulamak, tarihsel olarak en g\u00fc\u00e7l\u00fc sonu\u00e7lar\u0131 vermi\u015ftir; yeniden yat\u0131r\u0131lan Lilly temett\u00fcleri, yeniden yat\u0131r\u0131lmayan pozisyonlar\u0131 y\u0131ll\u0131k %2,7 oran\u0131nda ge\u00e7mi\u015ftir. Orta vadeli yat\u0131r\u0131mc\u0131lar (5-7 y\u0131l), genellikle portf\u00f6ylerinin %30-40'\u0131n\u0131 Lilly'ye tahsis ederek ve daha y\u00fcksek getirili ila\u00e7 hisseleriyle tamamlayarak b\u00fcy\u00fcme ve gelir hibrit yakla\u015f\u0131m\u0131ndan fayda sa\u011flarlar. An\u0131nda gelir art\u0131\u015f\u0131 arayan yat\u0131r\u0131mc\u0131lar, Pocket Option gibi platformlar arac\u0131l\u0131\u011f\u0131yla \u00f6rt\u00fcl\u00fc al\u0131m opsiyonu stratejileri uygulayarak, temel hisse senedi de\u011fer art\u0131\u015f\u0131na %70-80 kat\u0131l\u0131m sa\u011flarken, potansiyel olarak y\u0131ll\u0131k %4-6 ek gelir \u00fcretebilirler."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Eli Lilly (LLY) hissesinin mevcut temett\u00fc getirisi nedir?","answer":"Nisan 2025 itibar\u0131yla, Eli Lilly'nin temett\u00fc getirisi yakla\u015f\u0131k %0,75 seviyesindedir. Bu g\u00f6r\u00fcn\u00fc\u015fte m\u00fctevaz\u0131 getiri, yetersiz temett\u00fc \u00f6demelerinden ziyade ola\u011fan\u00fcst\u00fc hisse senedi fiyat\u0131 art\u0131\u015f\u0131n\u0131 yans\u0131tmaktad\u0131r. Pfizer gibi rakipler daha y\u00fcksek getiriler sunarken (%5,87), Lilly, mutlak temett\u00fc miktar\u0131n\u0131 y\u0131ll\u0131k %15,2 gibi sekt\u00f6r lideri bir oranda s\u00fcrekli olarak art\u0131rm\u0131\u015ft\u0131r -- bu oran S&P 500 ortalamas\u0131n\u0131n neredeyse \u00fc\u00e7 kat\u0131d\u0131r. Bu b\u00fcy\u00fcme odakl\u0131 yakla\u015f\u0131m, daha d\u00fc\u015f\u00fck ba\u015fl\u0131k getirisine ra\u011fmen \u00fcst\u00fcn toplam getiriler sa\u011flam\u0131\u015ft\u0131r."},{"question":"Eli Lilly ne s\u0131kl\u0131kla temett\u00fc \u00f6der?","answer":"Eli Lilly, Mart, Haziran, Eyl\u00fcl ve Aral\u0131k aylar\u0131nda genellikle \u00f6demeler yaparak temett\u00fcleri \u00fc\u00e7 ayda bir da\u011f\u0131t\u0131r. Bu \u00fc\u00e7 ayl\u0131k program, 1972'den beri tutarl\u0131 bir \u015fekilde devam etmekte olup, y\u0131l boyunca hissedarlara \u00f6ng\u00f6r\u00fclebilir gelir ak\u0131\u015flar\u0131 sa\u011flamaktad\u0131r. \u015eirket, da\u011f\u0131t\u0131mdan yakla\u015f\u0131k 45 g\u00fcn \u00f6nce kesin \u00f6deme tarihlerini duyurur ve bu bilgilere Eli Lilly'nin yat\u0131r\u0131mc\u0131 ili\u015fkileri portal\u0131 veya Pocket Option'\u0131n temett\u00fc takvimi \u00f6zelli\u011fi gibi finansal platformlar arac\u0131l\u0131\u011f\u0131yla ula\u015f\u0131labilir."},{"question":"Eli Lilly'nin temett\u00fc oran\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda temett\u00fcs\u00fc s\u00fcrd\u00fcr\u00fclebilir mi?","answer":"Eli Lilly'nin temett\u00fcs\u00fc, muhafazakar %42,1'lik \u00f6deme oran\u0131 sayesinde ola\u011fan\u00fcst\u00fc bir s\u00fcrd\u00fcr\u00fclebilirlik sergiliyor -- bu oran hem ila\u00e7 end\u00fcstrisi ortalamas\u0131n\u0131n (%63,4) hem de kendi tarihsel aral\u0131\u011f\u0131n\u0131n olduk\u00e7a alt\u0131nda. Bu disiplinli yakla\u015f\u0131m, kazan\u00e7 dalgalanmalar\u0131 d\u00f6nemlerinde bile temett\u00fc b\u00fcy\u00fcmesi i\u00e7in \u00f6nemli bir kapasite sa\u011flar. Bu s\u00fcrd\u00fcr\u00fclebilirli\u011fi destekleyen unsurlar aras\u0131nda Lilly'nin artan serbest nakit ak\u0131\u015f\u0131 (2023'te 8,9 milyar dolar, 2018'de 4,1 milyar dolardan), g\u00fc\u00e7l\u00fc bilan\u00e7o metrikleri (1,4x bor\u00e7\/EBITDA) ve 2030 sonras\u0131na kadar patent korumas\u0131 olan \u00e7\u0131\u011f\u0131r a\u00e7an ila\u00e7lar yer al\u0131yor."},{"question":"Eli Lilly'nin temett\u00fc b\u00fcy\u00fcmesi, ila\u00e7 end\u00fcstrisindeki rakipleriyle nas\u0131l kar\u015f\u0131la\u015ft\u0131r\u0131l\u0131r?","answer":"Eli Lilly, be\u015f y\u0131ll\u0131k %15,2'lik bile\u015fik y\u0131ll\u0131k b\u00fcy\u00fcme oran\u0131 (CAGR) ile ila\u00e7 end\u00fcstrisinin temett\u00fc b\u00fcy\u00fcme lideri olarak kendini kan\u0131tlam\u0131\u015ft\u0131r -- en yak\u0131n rakibi AbbVie'yi (%9,2) \u00f6nemli \u00f6l\u00e7\u00fcde geride b\u0131rakarak ve sekt\u00f6r ortalamas\u0131n\u0131 (%7,2) ikiye katlayarak. Bu ola\u011fan\u00fcst\u00fc b\u00fcy\u00fcme oran\u0131, Lilly'nin y\u00fcksek k\u00e2r marjl\u0131 tedavi alanlar\u0131na stratejik odaklanmas\u0131n\u0131, operasyonel verimlilik iyile\u015ftirmelerini ve y\u00f6netimin hissedarlara de\u011fer kazand\u0131rma konusundaki a\u00e7\u0131k taahh\u00fcd\u00fcn\u00fc yans\u0131tmaktad\u0131r. Pfizer (%3,2) ve Johnson & Johnson (%5,9) gibi rakipler daha y\u00fcksek ba\u015flang\u0131\u00e7 getirileri sunarken, Lilly'nin b\u00fcy\u00fcme odakl\u0131 yakla\u015f\u0131m\u0131 5 y\u0131ll\u0131k, 10 y\u0131ll\u0131k ve 20 y\u0131ll\u0131k d\u00f6nemlerde \u00fcst\u00fcn toplam getiri sa\u011flam\u0131\u015ft\u0131r."},{"question":"Eli Lilly'den temett\u00fc geliri elde etmek i\u00e7in en iyi strateji nedir?","answer":"Optimal strateji, yat\u0131r\u0131m zaman \u00e7izelgenize ve gelir gereksinimlerinize ba\u011fl\u0131d\u0131r. Maksimum uzun vadeli gelir b\u00fcy\u00fcmesine odaklanan 10+ y\u0131ll\u0131k ufuklara sahip yat\u0131r\u0131mc\u0131lar i\u00e7in, disiplinli bir DRIP (temett\u00fc yeniden yat\u0131r\u0131m plan\u0131) stratejisi uygulamak, tarihsel olarak en g\u00fc\u00e7l\u00fc sonu\u00e7lar\u0131 vermi\u015ftir; yeniden yat\u0131r\u0131lan Lilly temett\u00fcleri, yeniden yat\u0131r\u0131lmayan pozisyonlar\u0131 y\u0131ll\u0131k %2,7 oran\u0131nda ge\u00e7mi\u015ftir. Orta vadeli yat\u0131r\u0131mc\u0131lar (5-7 y\u0131l), genellikle portf\u00f6ylerinin %30-40'\u0131n\u0131 Lilly'ye tahsis ederek ve daha y\u00fcksek getirili ila\u00e7 hisseleriyle tamamlayarak b\u00fcy\u00fcme ve gelir hibrit yakla\u015f\u0131m\u0131ndan fayda sa\u011flarlar. An\u0131nda gelir art\u0131\u015f\u0131 arayan yat\u0131r\u0131mc\u0131lar, Pocket Option gibi platformlar arac\u0131l\u0131\u011f\u0131yla \u00f6rt\u00fcl\u00fc al\u0131m opsiyonu stratejileri uygulayarak, temel hisse senedi de\u011fer art\u0131\u015f\u0131na %70-80 kat\u0131l\u0131m sa\u011flarken, potansiyel olarak y\u0131ll\u0131k %4-6 ek gelir \u00fcretebilirler."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>lly hisse senedi temett\u00fcs\u00fc: Gelir Portf\u00f6y\u00fcn\u00fcz\u00fc %15,2 Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesiyle D\u00f6n\u00fc\u015ft\u00fcr\u00fcn<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"lly hisse senedi temett\u00fcs\u00fc: Gelir Portf\u00f6y\u00fcn\u00fcz\u00fc %15,2 Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesiyle D\u00f6n\u00fc\u015ft\u00fcr\u00fcn\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-22T15:59:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bradespar-Stock-Dividends-Exclusive-Strategies-to-Maximize-Your-Returns-in-2025.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1840\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Tatiana OK\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatiana OK\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/\"},\"author\":{\"name\":\"Tatiana OK\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"headline\":\"lly hisse senedi temett\u00fcs\u00fc: Gelir Portf\u00f6y\u00fcn\u00fcz\u00fc %15,2 Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesiyle D\u00f6n\u00fc\u015ft\u00fcr\u00fcn\",\"datePublished\":\"2025-07-22T15:59:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/\"},\"wordCount\":22,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bradespar-Stock-Dividends-Exclusive-Strategies-to-Maximize-Your-Returns-in-2025.webp\",\"keywords\":[\"investment\",\"pattern\",\"stock\",\"strategy\"],\"articleSection\":[\"Markets\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/\",\"name\":\"lly hisse senedi temett\u00fcs\u00fc: Gelir Portf\u00f6y\u00fcn\u00fcz\u00fc %15,2 Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesiyle D\u00f6n\u00fc\u015ft\u00fcr\u00fcn\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bradespar-Stock-Dividends-Exclusive-Strategies-to-Maximize-Your-Returns-in-2025.webp\",\"datePublished\":\"2025-07-22T15:59:13+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bradespar-Stock-Dividends-Exclusive-Strategies-to-Maximize-Your-Returns-in-2025.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bradespar-Stock-Dividends-Exclusive-Strategies-to-Maximize-Your-Returns-in-2025.webp\",\"width\":1840,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"lly hisse senedi temett\u00fcs\u00fc: Gelir Portf\u00f6y\u00fcn\u00fcz\u00fc %15,2 Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesiyle D\u00f6n\u00fc\u015ft\u00fcr\u00fcn\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d\",\"name\":\"Tatiana OK\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g\",\"caption\":\"Tatiana OK\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"lly hisse senedi temett\u00fcs\u00fc: Gelir Portf\u00f6y\u00fcn\u00fcz\u00fc %15,2 Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesiyle D\u00f6n\u00fc\u015ft\u00fcr\u00fcn","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/","og_locale":"tr_TR","og_type":"article","og_title":"lly hisse senedi temett\u00fcs\u00fc: Gelir Portf\u00f6y\u00fcn\u00fcz\u00fc %15,2 Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesiyle D\u00f6n\u00fc\u015ft\u00fcr\u00fcn","og_url":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/","og_site_name":"Pocket Option blog","article_published_time":"2025-07-22T15:59:13+00:00","og_image":[{"width":1840,"height":700,"url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bradespar-Stock-Dividends-Exclusive-Strategies-to-Maximize-Your-Returns-in-2025.webp","type":"image\/webp"}],"author":"Tatiana OK","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Tatiana OK"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/"},"author":{"name":"Tatiana OK","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"headline":"lly hisse senedi temett\u00fcs\u00fc: Gelir Portf\u00f6y\u00fcn\u00fcz\u00fc %15,2 Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesiyle D\u00f6n\u00fc\u015ft\u00fcr\u00fcn","datePublished":"2025-07-22T15:59:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/"},"wordCount":22,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bradespar-Stock-Dividends-Exclusive-Strategies-to-Maximize-Your-Returns-in-2025.webp","keywords":["investment","pattern","stock","strategy"],"articleSection":["Markets"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/","url":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/","name":"lly hisse senedi temett\u00fcs\u00fc: Gelir Portf\u00f6y\u00fcn\u00fcz\u00fc %15,2 Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesiyle D\u00f6n\u00fc\u015ft\u00fcr\u00fcn","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bradespar-Stock-Dividends-Exclusive-Strategies-to-Maximize-Your-Returns-in-2025.webp","datePublished":"2025-07-22T15:59:13+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bradespar-Stock-Dividends-Exclusive-Strategies-to-Maximize-Your-Returns-in-2025.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/07\/Bradespar-Stock-Dividends-Exclusive-Strategies-to-Maximize-Your-Returns-in-2025.webp","width":1840,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/knowledge-base\/markets\/lly-stock-dividend\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"lly hisse senedi temett\u00fcs\u00fc: Gelir Portf\u00f6y\u00fcn\u00fcz\u00fc %15,2 Y\u0131ll\u0131k Temett\u00fc B\u00fcy\u00fcmesiyle D\u00f6n\u00fc\u015ft\u00fcr\u00fcn"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/7021606f7d6abf56a4dfe12af297820d","name":"Tatiana OK","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0e5382d258c3e430c69c7fcf955c3ccdee2ae00777d8745ed09f129ffca77c26?s=96&d=mm&r=g","caption":"Tatiana OK"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/tatiana\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":319834,"slug":"lly-stock-dividend","post_title":"c\u1ed5 t\u1ee9c c\u1ed5 phi\u1ebfu lly: Bi\u1ebfn \u0110\u1ed5i Danh M\u1ee5c Thu Nh\u1eadp C\u1ee7a B\u1ea1n V\u1edbi T\u0103ng Tr\u01b0\u1edfng C\u1ed5 T\u1ee9c H\u00e0ng N\u0103m 15,2%","href":"https:\/\/pocketoption.com\/blog\/vt\/knowledge-base\/markets\/lly-stock-dividend\/"},"pt_AA":{"locale":"pt_AA","id":319829,"slug":"lly-stock-dividend","post_title":"dividendo de a\u00e7\u00f5es lly: Transforme Seu Portf\u00f3lio de Renda Com Crescimento Anual de Dividendos de 15,2%","href":"https:\/\/pocketoption.com\/blog\/pt\/knowledge-base\/markets\/lly-stock-dividend\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/319832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=319832"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/319832\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/308308"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=319832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=319832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=319832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}